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INTRODUCTION 
 
 
ROTAVIRUS 
 
 
Historical Background 
Rotaviruses are members of the Rotavirus genus of the Reoviridae family. Rotaviruses are 
recognized as the most important cause of severe viral gastroenteritis in humans and animals. 
Rotaviruses cause diarrheal disease primarily in the young people, but infection and disease in older 
children and adults can occur.  
Before 1972 no virus had been implicated as an important etiologic agent of gastroenteritis; 
techniques to identify nonbacterial agents (including viruses) were still rudimentary. 
In 1965, a retrospective study of hospital and laboratory records of patients was published (Ferris, 
1965) that demonstrated that most gastroenteritis in summer months could be attributed to infection 
with Salmonella sp. or Shigella sp., but there was clear evidence of winter epidemic peaks in 
children under 5 years of age, from whom no enteric pathogens (bacterial or viral) could be 
identified. The inability to identify a pathogen was considered to indicate a different (unknown) 
etiologic agent in winter months.  
In 1972, it was reported visualization of a small (27 nm) particle in faecal extracts from adult 
volunteers who had ingested faecal filtrates from adults with acute nonbacterial gastroenteritis. This 
virus was subsequently identified as a calicivirus, the Norwalk virus (Kapikian et al., 1972). 
In 1973, ultrathin sections of duodenal mucosa from children with acute gastroenteritis were 
examined, using electron microscopy. Abundant viral particles were identified in the epithelial cells 
lining the upper villous surface (Bishop et al., 1973). The virus was identified as being reovirus-
like/orbivirus-like, with a close resemblance to viruses already implicated in causation of diarrhea 
in neonatal mice (Adams et al., 1963) and in calves (Mebus et al., 1969). The virus could readily be 
identified (by electronmicroscopy of negatively stained faecal extracts) as 70-nm particles (Bishop 
et al., 1974). This virus was clearly different from the virus identified from adults.  
The 70-nm virus from children was initially referred to by several names, including reovirus-like, 
orbivirus-like, duovirus (because of its double layered structure), infantile gastroenteritis virus, or a 
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“new” virus. The wheel-like structure seen by electronmicroscopy led to agreement to accept the 
name Rotavirus (rota = Latin for wheel). Human Rotaviruses were quickly linked to previous 
descriptions in the literature of similar viruses causing severe diarrhea in newborn mice and calves, 
and to a virus identified from a rectal swab of a healthy monkey, SA11 (Malherbe et al., 1967). 
Rotaviruses have now been shown to be a cause of diarrhea in the young of many mammalian and 
avian species (Kapikian et al., 2001). 
One of the important consequences of this study was the successful initiative that removed 
antibiotic treatment from the Pharmaceutical Benefit List for pediatric gastroenteritis. 
 
 
 
 
Figure 1. Particles observed by electronmicroscopy in filtrates made from a stool of a child with 
gastroenteritis. The 70-nm reovirus-like agent. Bar = 100 nm [adapted from Kapikian et al., 1974]. 
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Classification 
Human Rotaviruses display diverse and complex serotypic specificities. In Rotavirus particles three 
concentric protein layers surround the double-stranded RNA viral genome and the viral capsid 
proteins are the majors determinants of antigenic properties of these viruses –group, subgroup, and 
serotypes.  
Viral protein (VP) 2 represents the core or inner capsid, whereas VP6 constitutes the middle capsid 
and is an important antigenic determinant that gives serogroup antigen specificity.  
 
 
 
Figure 2. Structure of Rotavirus. A cut-away of the viral structure is shown, with the proteins designated that 
make up each concentric protein layer [adapted from Estes, 2001]. 
 
The outer capsid is composed by VP7 (the glycoprotein or G-protein) and VP4 (the protease-
sensitive protein or P-antigen). These two proteins determine the serotype specificity and are the 
basis of the binary classification (G and P type) of Rotaviruses. Various combinations of VP4 and 
VP7 types have been observed in natural Rotavirus isolates. Virtually all Rotavirus genes are 
involved in reassortment events (Maunula et al., 2002). The extensive genomic and antigenic 
diversity of Rotaviruses of both human and animal origins has led to the proposal to classify 
Rotaviruses according to the composition of the whole genome (Matthijnssens et al., 2008; Maes et 
al., 2009). 
Currently Rotaviruses are classified into seven major groups (A to G). Group A, B and C 
Rotaviruses have been found in both human and animals; group D, E, F and G Rotaviruses have 
been found only in animals (Kapikian et al., 2001). Group A Rotaviruses have clearly been 
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established as causing severe diarrheal disease in the young (Hrdy, 1987); group B Rotaviruses 
include viruses that have been associated with annual epidemics of severe diarrhea primarily in 
adults (Yamamoto et al., 2010); group C viruses have been found in sporadic cases and outbreaks of 
diarrhea in piglets and children (Moon et al., 2010). VP6, which is a major determinant of group 
reactivity, is the target of common diagnostic assays and is used to further classify Rotavirus into 
subgroups I and II. VP7 (G) and VP4 (P) as previous reported are essential for serotype 
classification. 10 of 14 G serotypes and 8 P serotypes of Rotavirus occur in humans. 
 
 
Genome Structure 
Rotaviruses are members of the Rotavirus genus of the Reoviridae family. Member of this family 
are nonenveloped, with complex capsid containing several concentric protein layers displaying 
icosahedral symmetry.  
 
Rotavirus genome is composed of 11 segments of double-stranded RNA. The segments range in 
size from 667 (segment 11) to 3302 base pairs (segment 1), with the total genome containing 
approximately 18522 base pairs. Each segment is a gene that code for one protein, except gene 11 
which had two open reading frames and codified for NSP5 and NSP6 proteins. 
The nucleotide sequences of the 11 RNA segments from at least 53 different virus strains are 
known. There are general features about the structure of each of the 11 genome segments and 
sequences common to all RNA segments. Each RNA segment starts with a 5’ guanidine followed 
by a set of conserved sequences that are part of the 5’ noncoding sequences and another set of 
noncoding sequences, which contains a different subset of conserved 3’-terminal sequences and 
ends with a 3’-terminal cytidine, is found after the stop codon. The length of the 5’ and 3’ 
noncoding sequences vary for different genes; however, these lengths are conserved among strains 
for a given gene. Because of the conserved sequences of this 5’ and 3’ part of the genes, these 
terminal sequences are thought to contain signals important for genome transcription, replication, 
and possibly assembly of the viral genome segments. A polyadenylation signal is not been found at 
the 3’ end of the genes (Estes et al., 1989). 
All of the Rotavirus gene sequences are A+T rich (58 to 67%). 
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Figure 3. General scheme of Rotavirus genes structure [adapted from Estes, 2001]. 
 
 
Deproteinized, purified Rotavirus dsRNAs are not infectious, reflecting the fact that virus particles 
contain their own RNA-dependent RNA polymerase required to transcribe the individual RNA 
segments into active messenger RNAs (Cohen, 1977). 
 
 
Rotavirus Proteins 
The 11 dsRNA segments of the Rotavirus genome code for six structural (VP1-VP4, VP6 and VP7) 
and six non-structural proteins (NSP1-NSP6). 
The naming of the structural proteins (viral proteins, VP) is based on their molecular weights, with 
VP1, the largest at 125 kDa, and VP8, one of the two proteolytic fragments of VP4, the smallest at 
28 kDa. The six structural proteins form the multy-layered capsid of the mature Rotavirus particle. 
The nonstuctural proteins (NSPs) are synthesized in infected cells and function in some aspect of 
the viral replication cycle or interact with host proteins to influence pathogenesis or the immune 
response to infection. 
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Figure 4. Genome segments, proteins and structure of Rotavirus.  
The RNA segments are numbered in order of gel migration, and they are correlated with their encoded 
protein products by arrows. Gene segments 7, 8, 9 are very close in length and tend to migrate nearly on top 
of one another. Gene 11 is alternatively processed to produce NSP5 and NSP6. On the right, locations of the 
viral proteins in a Rotavirus particle [adapted from Prasad et al., 1996]. 
 
 
The development and application of RNA interference techniques offers an important tool to study 
the functional roles of rotaviral proteins during the process of infection (Arias et al., 2004; 
Campagna et al., 2005; Lopez et al., 2005). Furthermore, X-ray crystallography has been applied to 
determine the atomic structures of several structural and non-structural proteins of Rotavirus (Groft 
et al., 2002; Dormitzer et al., 2004). 
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Capsid Architecture 
The mature infectious Rotavirus particle (1000 Å in diameter, including the spikes) is made of three 
concentric icosahedral protein layers that encapsidate the genome. The complete virion is called a 
triple-layered particle (TLP). 
 
 
 
 
Figure 5. Rotavirus virion. The internal layer, or core, surrounds the viral genome, and contains the 
scaffolding protein VP2, the RNA-dependent RNA polymerase VP1, and the guanylyltransferase and 
methylase VP3. The intermediate layer is made of VP6, the major structural protein. The external layer is 
made up of VP7 and is decorated with spikes of VP4 [adapted from Angel et al., 2007]. 
 
 
VP7 Layer and VP4 Spikes 
The outer layer of the TLP is composed of two structural proteins: VP7 and VP4. VP7 (34 kDa), the 
major constituent of the outer layer, is a glycoprotein, although glycosylation is not required for 
capsid assembly (Estes, 2001). Seven hundred eighty copies of VP7 are grouped as 260 trimers.  
The outer layer is decorated by 60 spikes, each of which is formed by a dimmer of VP4 (88 kDa); 
thus each Rotavirus particle has 120 copies of VP4.  
From their locations in the structure of Rotavirus, VP7 and VP4 are obvious candidates to be 
implicated in the cell entry processes. Although early studies have implicated VP7 in the cell entry 
process (Fukuhara et al., 1988), subsequent studies have increasingly indicated the involvement of 
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VP4 not only in cell attachment and cell penetration, but also in hemagglutination, neutralization, 
virulence, and host range (Burns et al., 1988; Fiore et al., 1991; Ludert et al., 1998). Prior to its 
interaction with host cell, VP4 is proteolytically cleaved for efficient internalization of Rotavirus 
into cells. This is particularly relevant considering that Rotavirus replication takes place in 
enterocytes in the small intestine, an environment rich in proteases. Proteolytic cleavage of VP4 
enhances viral infectivity by several folds (Arias et al., 1996) and facilitates virus entry into cells 
(Kaljot et al., 1988). Proteolysis of VP4 generates two fragments, VP8 (aa 1-247, 28 kDa) and VP5 
(aa 248-776, 60 kDa), and these fragments remain associated with the virion (Fiore et al., 1991). 
 
 
Aqueous Channels 
One of the distinctive features of the Rotavirus architecture is the presence of large channels that 
penetrate through the VP7 outer layer and VP6 intermediate layer. These 132 channels allow for the 
passage of aqueous materials and biochemical substrates into and out of the capsid (Pesavento et al., 
2003). 
 
 
VP6 Layer 
The intermediate layer is formed by the VP6 protein (41 kDa). Particles carrying VP6 on the 
outside are called double-layered particles (DLPs). The VP6 layer maintains the same icosahedral 
symmetry as the VP7 layer with 780 copies of VP6 arranged as 260 trimers. These trimers are 
located right below the VP7 trimers such that the channels in the VP7 and VP6 layers are in 
register. 
The DLP is the transcriptionally competent form of the virus during the replication cycle. VP6 is 
the major protein of the Rotavirus particle by weight. It plays a key role in the overall organization 
of the Rotavirus architecture by interacting with the outer layer proteins, VP7 and VP4, and the 
inner most layer protein VP2. Thus it may integrate two principal functions of the virus: cell entry 
(outer layer) and endogenous transcription (inner layer). The X-ray structure of VP6 has been 
determined (Mathieu et al., 2001) and it shows that VP6 has two domains: the distal domain with an 
eight-stranded antiparallel β-sandwich fold makes contact with VP7 layer, and the lower domain, 
consisting of a cluster of α-helices, makes contact with the inner VP2 layer. 
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VP2 Layer and Transcription Enzyme Complex 
Underneath the VP6 layer is the innermost protein layer of Rotavirus structure. The particle 
structure at this level is referred as single-layer particle (SLP). The SLP houses the dsRNA genome 
in a protein layer composed of 120 copies of VP2 protein. VP2 is the only structural protein shown 
to possess nucleic acid-binding activity (Boyle et al., 1986). This internal layer, or core, contains 
also VP1 protein (an RNA-dependent RNA polymerase) and VP3 protein (a guanylyltransferase 
and methylase); VP1 and VP3 together form transcription enzyme complex. The question of how 
the dsRNA segments are arranged inside the capsid is particularly interesting considering that they 
are transcribed simultaneously and repeatedly in the confines of the capsid. A plausible model that 
emerges from the available biochemical and structure data for Rotaviruses and other dsRNA 
viruses, is that each genome segment is spooled around a transcription complex (consisting of VP1 
and VP3) that is anchored to the inner surface of the VP2 layer. Such a model allows for up to 12 
independent transcription complexes, each associated with an individual dsRNA segment for 
concurrent transcription (Pesavento et al., 2003). 
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Table 1. Properties of Rotavirus structural and non-structural proteins [adapted from Pesavento et al., 2006]. 
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Cell Entry 
Viral replication occurs in the mature epithelial cells of the small intestine, where Rotavirus infects 
nondividing differentiated enterocytes near the tips of the villus. 
Triple-layered particles (TLP) attach to host cell and enter by receptor-mediated endocytosis or 
direct penetration. The cellular receptors of RVs have not been fully characterized, but the 
consensus opinion that emerged from recent studies is that Rotavirus cell entry is a coordinated 
multistep process involving sequential interactions with sialic acid (SA)-containing receptors in the 
initial cell attachment step. Next, interactions occur with hsp70, and integrins during the subsequent 
post-attachment steps (Lopez et al., 2004). In the entry process, the VP8 domain is involved in the 
interactions with SA, whereas VP5 is implicated in the interactions with integrins. Involvement of 
SA during Rotavirus infections is not an essential step in all Rotavirus strains. For many of the 
Rotavirus strain, including human Rotaviruses, cell entry is SA-independent (Ciarlet et al., 2001), 
suggesting that cell entry is mediated mainly by the VP5. 
 
 
Endogenous Transcription 
During the process of cell entry, the outer layer is removed from TLPs by cellular enzymes and a 
low intracellular Ca
++
 level; in this way double-layered particles (DLPs) emerge. DLPs in the 
cytoplasm become transcriptionally active, and large number of positive-stranded RNA molecules 
(capped but not polyadenylated) is transcribed from all 11 RNA segments within the structural 
confines of the DLP (Estes et al., 2001). The nascent transcripts exit through channels that penetrate 
the inner VP2 and outer VP6 capsid layers of the DLP (Lawton et al., 1997).  
The DLP possesses the complete enzymatic activities needed to synthesize not only mRNA 
transcripts but also to properly guanylate and methylate the cap structure at the 5’ end of each 
mRNA to facilitate translation by the cellular translation machinery. These enzymatic functions are 
carried out by VP1, the RNA-dependent-RNA polymerase (Valenzuela et al., 1991), and VP3, a 
guanylyltransferase and methyltransferase (Chen et al., 1999). 
In the cytoplasm, the capped viral messenger RNAs are translated into proteins. 
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Figure 6. A DLP with mRNA transcripts exiting out by the proposed pathway through the capsid channels. 
The transcripts are represented as gray strands. On the right, a close-up view of a transcribing DLP [adapted 
from Lawton et al., 1997]. 
 
 
  
Genome Replication and Packaging 
The Rotavirus replication cycle consists of three subsequent major stages: 1) translation and 
synthesis of the viral proteins; 2) replication, genome packaging and DLP assembly; 3) budding of 
the newly formed DLPs into endoplasmatic reticulum (ER) and assembly of outer layer to form 
mature TLPs. 
The non-structural protein NSP3 is implicated in the specific recognition of rotaviral mRNAs and in 
facilitating their translation using the cellular machinery (Vende et al., 2000); while the N-terminal 
domain of NSP3 interacts with the 3’-consensus sequence of the rotaviral mRNAs, the C-terminal 
domain enables their delivery to the ribosomes for viral protein synthesis. 
Replication, genome packaging and assembly of the DLP occur in perinuclear inclusions called 
viroplasms, which appear 2-3 hours after infection. In the viroplasms, viral messenger RNAs are 
replicated to produce new genomic RNA. The proteins in the core of the incoming particles possess 
all the enzymatic activities required to produce the viral transcripts from the viral genome double-
stranded RNA because eukaryotic cells do not express RNA polymerases that transcribe mRNA 
from dsRNA templates (Greenberg et al., 2009). In particular, VP1 protein is an RNA-dependent 
RNA polymerase (Valenzuela et al., 1991). 
NSP2 and NSP5 proteins are the major components of viroplasms, and they are strongly implicated 
not only in the formation of the viroplasm, but also in genome replication and packaging. NSP5 is a 
dimeric phosphoprotein and interacts with both VP2 and VP1. NSP2 forms an octamer and has 
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NTPase (nucleotide triphosphatase), ssRNA binding, and helix destabilizing activities 
(Taraporewala et al., 2001); based on these properties, NSP2 may function as a molecular motor 
using the energy derived from NTP hydrolysis to facilitate genome packaging. The replication 
complex may be organized around the NSP2 octamer providing a platform or a scaffold (Jayaram et 
al., 2004). Co-expression of NSP2 and NSP5 in uninfected cells forms viroplasm-like structures and 
experiments of co-transfection with NSP5 and NSP2 have shown that NSP2 upregulates 
phosphorylation of NSP5 (Afrikanova et al., 1998). 
The exact order of events during early morphogenesis and the molecular interactions and control 
mechanisms by which genome replication, packaging and reassortment of RNA segments into cores 
occur are at present unknown (Desselberger et al., 2009). 
Also NSP6 is active in this process, but its role is still unclear; NSP6 interacts with NSP5 and it 
might have a regulatory role in the self-association of NSP5 (Torres-Vega et al., 2000). 
 
 
 
Figure 7. Scheme of Rotavirus replication cycle [adapted from Estes et al., 2001]. 
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Maturation and Release 
Currently is still not entirely clear how the set of 11 segments of dsRNA get encapsidates into each 
virion. The encapsidation could be concurrent with the capsid assembly (Pesavento et al., 2003). 
Thus, the capsid assembly begins with the association of 12 units, each unit consisting of pentamers 
of VP2 dimers in complex with a transcription enzyme complex (VP1/VP3) and a genome segment 
to form the SLP and provide a scaffold for the subsequent assembly of the VP6 trimers, leading to 
the assembly of a DLP. 
 
 
 
 
 
Figure 8. A working model for genome encapsidation in Rotavirus [adapted from Pesavento et al., 2003]. 
 
 
Once formed, DLPs bud from the viroplasms into the proximally located endoplasmatic reticulum 
(Estes, 2001) and, by a mechanism that is not clear, DLPs acquire the outer layer consisting of VP7 
and VP4. The non-structural protein NSP4, which has a binding site for VP6 in its C-terminal 
sequence, facilitates the budding process (O’Brien et al., 2000). Both NSP4 and VP7 are 
synthesized on the ER-associated ribosomes. 
NSP4 is also a viral enterotoxin capable of inducing diarrhea on its own in mice (Estes, 2003). 
During the budding process, DLPs get enveloped transiently in the ER. Silencing the expression of 
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VP7 does not affect the assembly of DLPs but leads to the accumulation of enveloped DLPs in the 
ER, suggesting that VP7 is required for removal of the lipid envelope (Lopez et al., 2005). Where 
and how the spike protein VP4, which is synthesized on cytosolic ribosomes, is assembled onto the 
particles is unclear. 
Triple-layered infectious virions are released by lysis of non-polarized cells or by exit from 
polarized cells, before a cytopathic effect becomes obvious (Estes, 2001). 
 
 
Transmission and Epidemiology 
Rotaviruses spread mainly via the faeco-oral route; there is also evidence to suggest that they can be 
transmitted in respiratory droplets (Parashar et al., 1998). Water, fomites and occasionally food may 
act as vehicles. Rotavirus particles are very resistant to environmental conditions. Primary infection 
is occurred before 5 years of age with Rotavirus peaks between 9 and 23 months of age with or 
without evidence of symptoms, (Parashar et al., 2006). Adults exposed to infected children have a 
high risk for contracting Rotavirus; although infection in adults is more frequently asymptomatic, 
Rotavirus is still shed in their stools and can therefore be transmitted to other people (Anderson et 
al., 2004). The high particle number in the faeces of children with acute Rotavirus disease and the 
very small 50% diarrhoea-causing dose [1 DD50 = 10 plaque forming units (pfu)] lead to wide 
spread to any susceptible host. While there are marked seasonal peaks (winter/spring) in countries 
with temperate climates, in tropical regions Rotavirus infections and disease occur throughout the 
year. 
According to the estimates based on studies carried out worldwide during 1986-2000, Rotaviruses 
cause 100 million episodes of acute gastroenteritis per annum. While the incidence of Rotavirus 
disease is similar for developed and developing countries, death from Rotavirus disease is most 
frequent in developing countries of sub-Saharan Africa and Asia (Parashar et al., 2003). In 
developing countries, Rotavirus gastroenteritis is responsible for more than 500.000 deaths each 
year, likely related to limited access to medical provisions (Parashar et al., 2006). Studies from 
Europe found that 50% of cases of gastroenteritis in children younger than 5 years of age were 
caused by Rotavirus and that the infection resulted in 230 deaths per year (Van Damme et al., 
2007). 
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Figure 9. Deaths due to diarrhoea per 100000 children younger than 5 years [adapted from Black et al., 
2008; WHO datas]. 
 
 
The epidemiology of Group A of Rotavirus infections is complex, since Rotaviruses of different G 
and P types co-circulate in a geographical region at any one time. The relative incidence of different 
G types also changes over time in the same location. Approximately 95% of co-circulating strains 
are G1-G4 in most regions of temperate climate, but other G types may be represented at high 
frequencies, particularly in tropical areas (Desselberger et al., 2001). Recently, G9 Rotaviruses have 
been isolated as the predominant outbreak strains in several locations in the USA and in Europe. 
 
 
 
Figure 10. Global distribution of Rotavirus serotypes [adapted from Stephen et al., 2008]. 
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Besides being acquired in the community, Rotavirus infections are increasingly recognized as the 
cause of a significant proportion of nosocomial infections and diarrheal disease (Gleizes et al., 
2006). Group B Rotavirus causes severe diarrhea primarily in adults; it has been detected recently in 
India, Bangladesh and Myanmar (Yamamoto et al., 2010). Group C Rotaviruses are associated with 
small outbreaks in humans worldwide (Moon et al., 2010). 
Apart from the accumulation of point mutations (genomic drift), gene reassortment (genomic shift) 
plays a major role in generating the high diversity of Rotaviruses (Iturriza-Gomara et al., 2001; 
Maunula et al., 2002). Animals of different mammalian species are increasingly recognized as 
significant reservoirs for human Rotavirus infections as animal Rotaviruses have been found to 
infect humans directly and to form reassortants with human Rotaviruses (Matthijnssens et al., 2008; 
Steyer et al., 2008). 
 
 
Pathogenesis 
Rotavirus infection can result in asymptomatic or symptomatic infection.  
In case of symptomatic infection, extensive cellular necrosis of epithelium of the small intestine 
develops, leading to villous atrophy, loss of digestive enzymes, reduction in absorption and 
increased osmotic pressure in the gut lumen and the onset of diarrhea. This is followed by a reactive 
crypt cell hyperplasia accompanied by increased fluid secretion, which also contributes to the 
severity of diarrhea. Rotavirus infection can lead to death. 
 
 
 
Figure 11. (A) Electron microscopy image of calf small intestine infected by Rotavirus. (B) Calf small 
intestine not infected [adapted from Madeley et al., 1975]. 
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Both host and viral factors affect the outcome of infection. The most prominent host factor that 
affects the clinical outcome of infection is age. Neonates infected with Rotavirus rarely have 
symptomatic disease; this protection is thought to be mediated by transplacental transfer of maternal 
antibodies (Ray et al., 2007). Reductions in these antibodies coincide with the age of maximum 
susceptibility of infants to severe Rotavirus-induced disease (range, three months to two years). 
Rotavirus can infect adults, but severe symptomatic disease is relatively uncommon and can result 
from infections with an unusual virus strain or extremely high doses of virus. 
Viral factors determining the pathogenicity of RVs have been investigated in several animal 
models, such as piglets, mice, and rabbits (Burke et al., 1996). The protein product of RNA segment 
4, VP4, is the major determinant of pathogenicity in several systems, but products of other 
structural (VP3, VP7) and non-structural genes (NSP1, NSP2, NSP4) are also implicated. NSP4 is 
the first described virus-encoded enterotoxin. It produces an increase in intracellular Ca
++
 
concentration (Berkova et al., 2003) and perturbs cellular electrolyte homeostasis. A peptide of 
NSP4, an active enterotoxin, is secreted from infected cells; the secreted protein binds cellular 
receptors and initiates signalling cascades in uninfected cells (Seo et al., 2008). 
Rotavirus can also stimulate the enteric nervous system (ENS), inducing secretory diarrhea and 
increasing intestinal motility (Lundgren et al., 2000). Drugs that inhibit the ENS are useful in 
treating Rotavirus diarrhea in children. 
Moreover Rotavirus infection is not limited to the intestine, but all infected individuals and animals 
undergo at least a short period of viremia and virus can be detected in the several other tissues of 
immunocompetent hosts; while viremia in Rotavirus infection appears to be frequent, systemic 
disease is rare (Ramig, 2007). 
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Figure 12. Mechanisms by which Rotaviruses cause diarrhea. (A) Events that occur after Rotavirus infection 
of enterocytes are shown in order from left to right. Not all events are shown in each cell. (1) Infection of the 
initial cell by luminal virus leads to virus entry, uncoating, transcription, translation of viral proteins, 
formation of viroplasms (Vi), and apical release of virus and viral protein. NSP4 (red triangle) and virus 
particles are released by a nonclassic secretory pathway. Intracellular NSP4 also induces the release of 
Ca2++, from internal stores, primarily the ER, leading to increasing [Ca++]i. (2) Another outcome can result 
from a cell being infected with virus. NSP4 produced by the infection disrupts tight junctions, allowing 
paracellular flow of water and electrolytes (blue arrow). (3) NSP4 released from previously infected cells 
binds to a specific receptor and triggers a signaling cascade through phospholipase C (PLC) and inositol 
phosphatase (IP)3 that results in release of Ca2++ and an increase in [Ca2++]i. Intracellular expression of 
NSP4 increases [Ca2++]i through a PLC-independent mechanism. The increase in [Ca2++]i also disrupts the 
microvillar cytoskeleton. (4) A crypt cell (brown) can be acted on directly by NSP4, or NSP4 can stimulate 
the enteric nervous system (ENS), which in turn signals an increase in [Ca2++]i that induces Cl- secretion. (B) 
Normal architecture of the small intestine, without the circulatory system shown. The ENS and its ganglia in 
the different submucosal levels are shown. (C) Reflex arc in the ENS that can receive signals from the villus 
epithelium and activate the crypt epithelium. Inset 1 shows a whole-mount of an adult mouse small intestinal 
villus stained with antibody to the gene product 9.5 neuroendocrine marker to reveal the rich innervation 
(yellow). Inset 2 shows that infected villus enterocytes can stimulate the ENS by the basolateral release of 
NSP4 or other effector molecules. The integrin α2β1 can bind NSP4 and elicit diarrhoea in neonatal mice 
[adapted from Ramig, 2004]. 
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Diagnosis 
Diagnosis of a Rotavirus infection is relatively easy as large numbers of virus particles (up to 10
11
 
particles/ml of faeces) are shed at acute stage of the disease. The main techniques are enzyme-
linked immunoassays (ELISAs) and, when searching comprehensively for diarrhoeagenic viruses, 
electronic microscopy (EM). G and P types of Rotavirus isolates can be determined serologically, 
but molecular techniques are increasingly being applied for both detection and genotyping. 
Rotavirus-specific oligonucleotide primers complementary to VP6, VP7 and VP4 sequences allow 
sensitive detection, subgroup determination and typing for both G and P types by RT-PCR 
(Maunula et al., 2002; Simpson et al., 2003; Matthijnssens et al., 2008). 
 
 
Immunity 
Rotavirus-induced immune responses, especially the T and B cell responses, have been extensively 
characterized; however, little is known about innate immune mechanism involved in the control of 
Rotavirus infection. 
Protective Rotavirus immunity is multifactorial, achieved through the combined action of secretory 
antibodies, humoral and cell-mediated immunity. In adult mice have been shown that, after 
infection with a homologous murine Rotavirus, CD8
+
 T cells have a role in the timely resolution of 
primary infection and B cells are necessary for long-term robust protection against Rotavirus 
(Franco et al., 2001). CD4
+
 T cells have an important, but non essential, role in supplying help to 
CD8+ T cells and B cells; in particular, CD4
+
 T cells contribute to generate Rotavirus-specific 
intestinal immunoglobulin A (IgA), which is the principal effector of long-term protection against 
Rotavirus infection (Franco et al., 1999). As would be expected by the fact that Rotavirus infection 
includes a viraemic phase (Fenaux et al., 2006; Blutt et al., 2007), both intestinal and systemic 
Rotavirus-specific B cell responses are observed in mice. However, only Rotavirus-specific plasma 
cells that reside in the intestine seem to have an antiviral effect, suggesting that mucosal, but not 
systemic, antibodies provide protection in this model (Franco et al., 2006). Humoral antibodies, 
directed towards VP2 and particularly VP6 proteins, are produced to high titers after Rotavirus 
infection (Burns et al., 1996). The induction of neutralizing antibodies in neonatal mice (Smiley et 
al., 2007) and pigs (Yuan et al., 2000) after infection with homologous Rotavirus is relatively weak; 
it could, in part, be due to the immaturity of their immune system. 
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In agreement with the animal studies, the levels of Rotavirus-specific serum IgA, measured shortly 
after natural infection in children, generally correlate with intestinal IgA levels and in many, but not 
all studies, the serum IgA level provides a good correlate of protection (Franco et al., 2006). 
Furthermore, T-cell responses to Rotavirus are related to the development of protective antibodies 
(Offit et al., 1993), even if the T-cell response to Rotavirus in humans, as in animal models, seems 
to be transient and of low intensity, especially in Rotavirus-infected children, in fact, the T-cell 
response appears to be more robust in adults (Kaufhold et al., 2005). 
The innate immune response is also very important. Rotavirus infection results in the secretion of 
type I interferon (IFNα and IFN β), presumably from a plasmacytoid subset of dendritic cells, pDCs 
(Mesa et al., 2007). While increased levels of IFNα have also been correlated with a positive 
clinical outcome in infected children (Mangiarotti et al., 1999), several Rotaviruses have recently 
been demonstrated to antagonize the production of type I IFN through the degradation of interferon 
regulatory factors (IRF) 3, IRF5, and IRF7 (Barro et al., 2007). NSP1 recognizes a common 
element of IRF proteins, thereby allowing NSP1 to act as a broad-spectrum antagonist of IRF 
function. IRF5 also has roles in stimulating the expression of cytokines and chemokines that cause 
the recruitment of T lymphocytes (Yanai et al., 2007); interaction between NSP1 and IRF5 can 
downregulate the activation of genes producing proinflammatory cytokines that initiate events 
leading to apoptosis, so that the Rotavirus can exist longer in infected cells. 
This response is dependent on the presence of the viral dsRNA genome. As IFNα production by 
pDCs is classically trigged in response to ssRNA or DNA, the induction of this response by a 
dsRNA virus indicates a potentially novel mechanism of viral sensing by pDCs (Deal et al., 2010). 
Rotavirus NSP1 also inhibits nuclear factor κB (NFκB) activation (Graff et al., 2009). NFκB 
induces the production of IFNβ and chemokines, both of which have antiviral effects; thus 
Rotavirus bloks NFκB activity to delay the innate immune response. 
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Figure 13. Potential mechanisms of Rotavirus pathogenesis and immunity. The mechanisms of Rotavirus 
pathogenesis and immunity are not completely understood and vary depending on the animal species studied. 
In step 1, neutralizing antibodies directed against VP4 and/or VP7 can prevent viral binding and penetration, 
inducing viral exclusion. If this mechanism fails, as shown in step 2, Rotavirus replication inside enterocytes 
causes altered metabolism of enterocyte membrane proteins inducing malabsorptive or osmotic diarrhoea. 
Rotavirus also increases the concentration of intracellular calcium, which disrupts the cytoskeleton and the 
tight junctions, raising the paracellular permeability. During step 3, intracellular viral replication can be 
inhibited by secretory anti-VP6 immunoglobulin A (IgA) during transcytosis across enterocytes. In step 4, 
cytokine-secreting Rotavirus specific T cells can also inhibit viral replication. If viral replication is not 
stopped, as shown in step 5, replicating Rotavirus produces non-structural protein 4 (NSP4), a toxin which 
induces a secretory non-cystic fibrosis transmembrane conductance regulator (CFTR)-mediated diarrhoea. 
By an unknown mechanism Rotavirus can also stimulate the enteric nervous system (ENS) (as shown in step 
6), inducing secretory diarrhoea and increasing intestinal motility. Drugs that inhibit the ENS are useful in 
treating Rotavirus diarrhoea in children. Antibodies against NSP4 could potentially have an effect against the 
last two mechanisms. Late in the infectious process, Rotavirus kills the host cell (as shown in step 7), further 
contributing to malabsorptive or osmotic diarrhoea [adapted from Angel et al., 2007]. 
 
 
Natural infection or appropriate vaccination seems to protect from severe disease in subsequent 
infections (Velazquez, 2009), even if the serotype of the challenging virus differs from that of 
previous infections or those in a prior vaccine. 
 
 
Vaccine Development 
The worldwide burden of disease because of Rotavirus quickly led to initiatives supported by the 
World Health Organization (WHO) to develop vaccines to prevent this disease. The vaccine 
initiative was developed in parallel with initiatives aimed at widespread extension of oral 
rehydration therapy in developing countries. 
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The development of vaccines against Rotavirus started in the early 1980s. Animal Rotaviruses (of 
simian or bovine origin) were used as live attenuated vaccines for humans. 
A tetravalent vaccine contained a rhesus Rotavirus (RRV) of G3 type and three mono-reassortants, 
which individually carry the VP7 gene of human serotypes G1, G2 and G4 in the RRV genetic 
background (Rotashield
®
).  This vaccine was highly effective (80-100%) in preventing severe 
diarrheal disease, even if the immunologic basis for this efficacy was unclear. It received Food and 
Drug Administration approval as a universal vaccine in the USA in 1998. More then 1.5 million 
doses were administrated in the followed 10 months. During that time, several cases of 
intussusception were observed in vaccinees, particularly within 3-7 days after the first dose 
(Murphy et al., 2001); these observations led to withdraw the recommendation of Rotashield for use 
in infants, and vaccine production ceased. A recent re-analysis of the data indicated that the age of 
vaccinees is a critical factor for intussusception, as a disproportionately high number (>80%) of 
children who developed intussusception after the first dose of Rotavirus vaccine were older than 90 
days leading to the consideration those vaccinations in children older than 3 months 
contraindicated. 
It took another 7 years before new Rotavirus vaccine candidates were available.  
In 2006 two new live-attenuated Rotavirus vaccines were licensed in the United States, the 
European Union, as well as many countries in Central and South America.  
In one of these new vaccines, a bovine Rotavirus strain (WC3), isolated in the United States, was 
used as a backbone to create a pentavalent vaccine that contained 5 separate viruses that expressed 
either human G1, G2, G3, or G4 VP7s, and human P(8) VP4 on the bovine WC3 backbone. This 
vaccine is manufactured by Merck and it is called RotaTeq
®
. It was found to be highly efficacious 
in preventing severe Rotavirus gastroenteritis (98%) caused by G1, G2, G3, G4 and G9 strains 
(Vesikari et al., 2006).  
RotaTeq
®
 is given in a three-dose schedule and preliminary data indicate that at least two doses are 
required to generate significant levels of protection (Vesikari, 2008). The vaccine is given by 
mouth; the first dose is given from 6 to 12 weeks of age, the second dose is given 4 to 10 weeks 
later. The last (third) dose should be given by 32 weeks of age.  No link between RotaTeq
®
 and 
intussusception was found (Vesikari et al., 2006).  
Another vaccine was licensed in 2006. GlaxoSmithKline manufactures this vaccine under the trade 
name Rotarix
®. It’s a monovalent vaccine derived from an attenuated human Rotavirus isolate of 
the G1P1A[8] type. The rationale underlying the development of Rotarix
®
 was that a single natural 
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Rotavirus infection provides protective immunity against subsequent severe disease, irrespective of 
serotype (Velazquez et al., 1996). Therefore, it seemed logical to predict that an attenuated human 
Rotavirus strain might do the same. The virulent G1 human Rotavirus strain was passaged for 
multiple rounds in monkey kidney cell cultures to achieve attenuation. The initial passaged material 
possessed virulence, but after subsequent additional passages and plaque purification, a highly 
attenuated product was attained. As with RotaTeq
®
, the molecular basis for the attenuation of the 
Rotarix
®
 vaccine is unknown. Rotarix
®
 provided good heterologous protection against G2, G3, G4 
and G9 type, and obviously against G1 type.  
Rotarix
® 
requires only two doses, probably because it is better adapted to replication in the human 
gastrointestinal tract than the bovine-based vaccine, and it can be administered at a dose 
approximately 100-fold lower than that of RotaTeq
®
. The vaccination series consists of two 1-ml 
doses administered by mouth. The first dose can be given beginning at six weeks of age and the 
second at least four weeks after the first dose, but before the child reaches 24 weeks of age.  
Rotarix
®
 is 85% effective against preventing severe diarrhea and no association between this 
vaccine and intussusception is known (Ruiz-Palacios et al., 2006). 
 
 
 
Figure 14. The Rotarix® and Rotateq® vaccines. a. Rotarix® is an attenuated human Rotavirus vaccine made 
of a tissue culture-adapted human P1A[8]G1, VP6 and NSP4 geno-group B strain. b. RotaTeq® is a bovine 
(WC3)–human reassortant vaccine composed of the five strains shown, each containing a human Rotavirus 
gene encoding the VP7 neutralizing protein from different serotypes. Notably, in the WI79-9 and SC2-9 
viruses (the last was used to create the first), genes 3 (VP3) and 9 (VP7) are of human origin. Although VP6 
and NSP4 can potentially be the targets of protective antibodies, their role in immunity against disease in 
humans is unknown [adapted from Angel et al., 2007]. 
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Nowadays the risk of desirable effects of live attenuated vaccines (clinical complications, reversion 
to virulence, genetic interaction and reassortment with co-circulating wildtype Rotavirus strains, 
etc.) is considered to be low, but not zero. Thus several third-generation Rotavirus vaccines are in 
development because of possible safety issues associated with the use of RotaTeq
®
 and Rotarix
®
, 
and several groups are pursuing recombinant virus-like particles approaches. 
 
 
Rotavirus-Like Particles (VLPs) 
Virus-like particles (VLPs) are a highly effective type of subunit vaccines that mimic the overall 
structure of virus particles without any requirement that they contain infectious genetic material. 
Indeed, many VLPs lack the DNA or RNA genome of the virus altogether, but have the authentic 
conformation of viral capsid proteins, without any of the risks associated with virus replication or 
inactivation (Roy et al., 2008). 
The fact that VLPs mimic the structure of the virus particles usually means that VLPs elicit strong 
humoral response. In addition to their ability to stimulate B cell mediated immune responses, VLPs 
have also been demonstrated to be highly effective at stimulating CD4 proliferative and cytotoxic T 
lymphocyte (CTL) responses (Schirmbeck et al., 1996).  
To date, VLPs have been produced for many different viruses that infect humans and other animals.  
VLPs have also been produced for Rotavirus. VLPs formed from the two inner structural proteins of 
the Rotavirus capsid (VP2 and VP6) have been shown to be effective immunogens in animal 
models (Parez et al., 2006). The expression of VP2 alone results in the production of pseudo-core 
particles (Zeng et al., 1994). VP6 alone can form spherical or tubular aggregates (Lepault et al., 
2001); VP6 self-assembles into different types of particles depending on conditions such as pH, 
ionic strength and divalent cation concentration. 
Moreover virus-like particles provide the spatial structure for the repetitive, high density display of 
conformational epitopes and can be exploited as platforms for the presentation of foreign epitopes 
or targeting molecules on chimeric VLPs (Peralta et al., 2009). It has been reported that 
heterologous proteins as green fluorescent protein (GFP) could genetically fused to VP2 and 
incorporated into VLP (Charpilienne et al., 2001); to assure the correct VLP assembly, it is 
considered that molecules smaller than 250 amino acids could easily be integrated into this delivery 
system by fusion to VP2 protein. A foreign epitope could also fused to VP6, because the ability of 
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VP6 to form multimeric structures and the strong immune responses that VP6 can elicit in different 
species (Peralta et al., 2009). 
Rotavirus exhibits a marked tropism for intestinal epithelium. As Rotavirus-like particles display 
properties very similar to those of Rotavirus, their natural tropism and nonreplicative properties 
make these VLPs a viable alternative to the live virus vaccine for Rotavirus and a promising safe 
candidate for drug delivery to intestine in pathologies such as inflammatory bowel diseases (IBD) 
(Cortes-Perez et al., 2010). 
 
 
Update on Recommendations for the Use of Rotavirus Vaccines (by Food and 
Drug Administration, FDA) 
On March 2010, FDA provided an early communication regarding Rotarix
® 
(GlaxoSmithKline) 
while the agency and manufacturer investigated the finding of DNA from porcine circovirus type 1 
(PCV1) in the vaccine. Since that time, both FDA and GSK have confirmed the presence of PCV1 
in the vaccine, FDA recommended that clinicians and public health professionals in the United 
States temporarily suspend the use of Rotarix
®
. 
On May 2010, FDA provided information about RotaTeq
®
 (Merck). FDA indicated that preliminary 
studies conducted by Merck identified fragments of DNA from PCV1 and from a related porcine 
circovirus type 2 (PCV2) in RotaTeq
®
.  
PCV1 and PCV2 are both small viruses composed of a single strand of circular DNA. Both viruses 
are common in pigs. Neither PCV1 nor PCV2 are known to infect or cause illness in humans, 
however PCV2 may cause illness in pigs. 
At the end of May 2010, based on careful evaluation of a variety of scientific informations, FDA 
has determined it is appropriate for clinicians and health care professionals to resume the use of 
Rotarix
® 
and to continue the use of RotaTeq
®
 (because there is no evidence that these findings pose 
a safety risk in humans). 
On October 2010, Merck and FDA’s laboratories determined that there is no evidence of the 
presence of PCV2 in RotaTeq
®
. 
 
 
 
 
INTRODUCTION 
 31 
Communication of AIFA (Agenzia Italiana del Farmaco) 
On July 2010, AIFA (Agenzia Italiana del Farmaco) overturns the prohibition to use Rotarix
®
 and 
RotaTeq
®
 (decided on April 2010 and July 2010 respectively) because the ratio benefit/risk of these 
vaccines continues to be positive. However the presence of exogenous DNA in these vaccines must 
be eliminated. 
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HERPESVIRUS-1 
 
 
Virion Stucture 
The Herpes simplex virus type 1 (HSV-1) is an enveloped, double-stranded (ds) DNA virus. The 
DNA virus genome is enclosed into an icosahedric capsid, which is surrounded by the tegument, a 
rather unstructured layer containing some twenty virus-encoded proteins with structural and 
regulatory roles. The tegument is delimited by the envelope, which is a lipid membrane of cellular 
origin, containing a dozen virus-encoded glycoproteins.  
 
 
 
HSV-1 enters epithelial cells and neurons by fusion of the virus envelope with the plasma or 
endosomal membranes, and the virus capsid are transported to the nuclear pores through association 
with microtubules (Marozin et al., 2004), from where the viral DNA is then released into the 
nucleus. The HSV genome can be viewed as consisting of two covalently linked components, 
designated as L (long) and S (short); each component consists of unique sequences bracketed by 
inverted repeats. During lytic infection, the virus 153-kilobase pairs (kbp) double-stranded DNA 
genome expresses at least 84 genes that are temporarily regulated in a cascade fashion, giving rise 
to three phases of gene expression. The expression cascade, which is regulated mainly at the 
transcriptional level, begins with the expression of the immediate-early (IE) genes. Five viral IE 
genes are expressed first, and four of these encode regulatory proteins (ICP0, ICP4, ICP22 and 
ICP27) that are responsible for controlling viral gene expression during subsequent, early (E) and 
late (L) phases of the replication cycle and for inducing shutoff of cellular protein synthesis. 
Transcription of IE genes occurs in the absence of de novo viral protein synthesis and is highly 
Figure 15. HSV-1 particle observed by electron microscopy [adapted from J.Brown]. 
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stimulated by a virion protein known as VP16, which is a powerful transcription factor that, in 
conjunction with cellular proteins, acts on DNA motifs present only in the IE regulatory regions to 
up-regulate expression. The early (E) gene products that are synthesized next include enzymes that, 
like thymidine kinase and ribonucleotide reductase, act to increase the pool of deoxynucleotides of 
the infected cells, and several replication proteins that are directly involved in viral DNA synthesis. 
The last functions to be expressed are the late (L) genes, which encode proteins involved in the 
packaging of virus DNA, as well as the structural proteins involved in the assembly of the virion 
particle, including the capsid, the tegument, and the envelope. Some of these structural proteins, 
like the tegumentary VP16, play major regulatory roles in the next infectious cycle. Capsids are 
assembled in the nucleus but the tegument and the envelope are acquired in the cytoplasm, most 
probably by budding into endosomes, and are released by exocytosis at cell membranes (Skeeper et 
al., 2001). 
 
 
 
 
HSV-1 Lytic and Latent Cycles 
After initial infection and lytic multiplication at the body periphery, generally at oral or genital 
epithelial cells, HSV enters the sensory neurons that innervate the infected epithelia and, following 
retrograde transport of the capsid to the cell bodies, establishes a lifelong latent infection in sensory 
ganglia. Periodic reactivation from latency usually leads to the return of the virus to epithelial cells, 
where it produces secondary lytic infections resulting in mild illness symptoms, such as cold sores. 
Figure 16. (A) Genome structure of HSV-1. TR: Terminal Repeats; IR: Internal Repeats. (B) Schematic 
representation of cascade mechanism of genic expression in HSV-1. IE: Immediate Early genes; E: 
Early genes; L: Late genes. 
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In rare cases, HSV-1 can spread centripetally into the central nervous system, to cause devastating 
encephalitis (Roizman et al., 2001). 
 
Lytic viral replication results in the impairment of host macromolecular synthesis, the release of 
newly assembled viral progeny particles and the ultimate death of the host cell. A striking property 
of the virus life strategy is the high number of functions devoted to avoid or inhibit inimical cellular 
responses that could eventually block or diminish virus expression and multiplication. These 
functions, which actually represent more than 10% of the virus genome, include many proteins that 
act to counteract the innate immune responses, to inhibit the proapoptotic response of the cells to 
virus infection, and to facilitate escaping from the adaptive immune system (Mossman et al., 2005). 
 
 
 
Figure 17. Schematic representation of HSV-1 replication cycle.  
The attachment of the virion to the surface of the cell is followed by viral entry into cell. Then the virion 
is transported to the cell nucleus, where the cascade mechanism of gene expression takes place. In the 
nucleus capsid assembly and the cleavage of HSV-1 progeny DNA concatamers into unit-length 
monomers occur. After encapsidation of full-length DNA molecules, the nucleocapsid is capable of 
budding through the inner nuclear membrane, and then the virus particle is released through secretory 
vesicles. 
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During latency in sensory neurons, the viral genome remains as a circular chromatinized episome 
(Deshmane et al., 1989) within the cell nuclei, and undergoes dramatic changes resulting in an 
almost complete silencing of transcription. Only one region of the viral genome, known as the LAT 
locus, is actively transcribed during latency, due to the presence of a latency associated promoter 
(LAP) that remains active during this phase of the infection, resulting in the synthesis of non-
messenger RNA molecules of unknown function (the latency associated transcripts, or LATs), 
which accumulates in the nucleus of the latently infected neurons (Farrell et al., 1991). Very 
recently, the LAT locus has been shown to express one class of miRNA molecules that can down-
regulate expression of cellular proteins like TGF-1 and SMAD 3, and which seems to play an anti-
apoptotic role during latency or reactivation (Gupta et al., 2006). The latent virus genome can 
reactivate in responses to a wide variety of stimuli that allow it to enter the lytic phase of the HSV-1 
life cycle (Preston, 2000). 
 
 
 
 
 
HSV-1 and its Derived Vectors 
The uniqueness of HSV-1-based vectors stems from outstanding properties of HSV-1, not shared 
with any other viral system.  HSV displays a broad host cell range, the very large capacity of the 
virus particle, which allows packaging and efficiently delivery of up to 150 kbp of DNA to the 
Figure 18. Latency and reactivation of HSV-1. 
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nuclear environment of mammalian cells. The complexity of the virus genome, which contains 
some 40 genes that are not essential for virus replication, allows deletion of these genes without 
disturbing virus production in culture conditions, yet they are required for expression of a fully 
virulent phenotype in vivo. Other interesting property is that the viral DNA will not integrate into 
host chromosomes, thus reducing the risk of insertional mutagenesis, and the genes carried by these 
molecules will be expressed from the episomic genome. 
Three different types of vectors can be derived from HSV-1, which attempt to exploit one or more 
of the previously described properties. Recombinant HSV-1 vectors are created by replacing one or 
several virus genes with transgene sequences. Depending on the virus genes that are replaced, 
recombinant HSV-1 vectors can be replication-competent, -conditional, or –defective.  The choice 
of the replicative state of a vector depends on the purpose of gene delivery and the target tissue. 
Attenuated recombinant vectors are replication-competent HSV-1, generally carrying attenuating 
mutations that restrict spread and lytic viral replication to a limited number of tissues, without 
causing major toxicity to the inoculated organism. Defective recombinant vectors are disabled, 
replication incompetent and non-pathogenic HSV-1 mutants lacking one or more essential genes. 
These vectors retain many advantageous features of wild-type HSV-1, particularly the ability to 
express transgenes after having established latent infections in central and peripheral neurons, but 
cannot replicate in, and therefore cannot disseminate out of, the infected cells. Lastly, amplicon 
vectors are defective, helper-dependent vectors that take advantage essentially of the large 
transgenic capacity of the virus particle. Actually, there is no other mammalian vector available that 
could equal the ability of herpesvirus-based amplicons to deliver 150 kbp of foreign DNA with no 
simultaneous delivering of viral genes.  
In all three cases, the vector particles are basically identical to the wild type HSV-1, which are 
complex particles made up of some 40 different virus encoded structural proteins. These proteins 
will be delivered into the cell during infection and can trigger cell signalling and cellular responses 
and, consequently, may have a transient impact on the cell homeostasis and gene expression. 
However, at least when using defective vectors not expressing virus genes, such as amplicons, the 
imported structural proteins will soon disappear and the cells will resume their normal functions, 
including the ability to divide and to respond to physiological stimuli. Although the HSV-1-based 
vectors have been used mainly for gene transfer to neurons, they can efficiently deliver genes t o 
other cell types, including epithelial cells, myoblasts, myotubes, embryonic and adult 
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cardiomyocytes, hepatocytes, and cell lines derived from gliomas, hepatocellular carcinomas, 
osteosarcomas, epidermoid carcinomas and many other human and murine malignancies. 
 
 
Defective Recombinant Vectors 
These vectors are disabled, replication-incompetent and non-pathogenic mutant viruses that lack 
one or more genes encoding essential proteins, but retain many advantageous feature of wild-type 
virus, particularly the ability to express transgenes. Various aspects of these vectors are attractive 
when considering the design of gene therapy vectors. These include a broad host cell range, the 
ability to efficiently transduce dividing and non-dividing cells, the large capacity of their genomes, 
allowing introduction of more than 30 kbp of foreign DNA, and the latent behaviour of the virus, 
which may be exploited for the stable long-term expression of therapeutic transgenes in neurons.  
Non-replicative HSV-1 recombinants are potential vectors for several applications in human health. 
These include delivery and expression of human genes to central nervous system cells, selective 
destruction of cancer cells, prophylaxis and immunotherapy against tumors and prophylaxis against 
HSV-1 and other infectious disease. Each application requires a different kind of vector and, in 
principle, different kinds of genetic engineering. Some gene therapy applications will require short-
term transgene expression, while others will demand a long-term or regulated expression of the 
exogenous gene. Although delivery of a single gene should be adequate in many cases, other 
applications will likely require the delivery of multiple transgenes. One of the major advantages of 
non-replicative vectors is the possibility, due to their capacity to accommodate multiple transgenes 
in one vector, to achieve a synergistic therapeutic effect in gene therapy applications of 
multifactorial diseases. 
In HSV-1 virus immediate-early genes (IE), which encode ICP0, ICP4, ICP22, ICP27 and ICP47, 
are expressed shortly after viral entry into host cell and are required for initiation of the cascade of 
early (E) and late (L) viral gene transcription. ICP4 and ICP27 are essential for replication and the 
deletion of one or both of them requires adequate complementing cell lines that provide in trans the 
missing function (Marconi et al., 1996; Wu et al., 1996). The “first generation” of replication-
defective HSV-1 based vectors consisted of mutants deleted in the single essential IE encoding 
ICP4, namely dl20 and S4TK vectors (Krisky et al., 1997). Although these vectors show reduced 
pathogenicity, they possess some residual cytotoxicity that probably results from the expression of 
the other four IE genes. ICP4, ICP27, ICP0, and ICP22 have all been shown to be toxic in stable 
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transfection assays (Wu et al., 1996), so deletion of these genes in combination is required to 
eliminate toxicity (Krisky et al., 1998; Moriuchi et al., 2000). Cell lines that complement ICP4 and 
ICP27 have permitted the construction of a “second generation” of highly defective mutants 
(Marconi et al., 1999). To date, several replication-defective vectors have been constructed in which 
ICP0, ICP4, ICP27, ICP22 and ICP47 genes have been deleted in various combinations. The second 
generation of replication-defective vectors is characterized by absence of early and late viral gene 
expression and provide enough space to introduce distinct and independently regulated expression 
cassettes for different transgenes (Krisky et al., 1998). Deletion of all five IE genes prevents virus 
cytotoxicity at high multiplicity of infection, allowing the vector genome to persist in cells for long 
periods of time. However, these vectors grow poorly in culture and express transgenes at very low 
levels in the absence of ICP0 transactivator (Samaniego et al., 1997). 
 
 
 
Figure 19. Defective recombinant vectors lack one or more genes encoding essential proteins and they grow 
only in adequate complementing cell lines that provide in trans the missing function. 
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HSV-1-Based Vectors for Vaccination 
Replication defective HSV-1 virus makes attractive vaccine vectors in that they are highly 
infectious for an extremely broad host cell range, including dendritic cells. They express transgenes 
within cells, so the antigens can be presented efficiently by both MHC class I and class II pathways, 
and can activate the innate immune system through Toll-like receptors (Kurt-Jones et al., 2004). 
Various non-replicative HSV-1 viruses, deleted in one or more of the immediate-early genes, have 
been successfully used as vaccine vectors in murine and simian models.  
Due to the high prevalence of HSV-1 infection within the human population, a possible drawback to 
the use of HSV-1-based vectors is the presence of pre-existing anti-HSV-1 immunity and its 
potential ability to reduce vector efficacy. The effect of pre-existing immunity on HSV-1 vectors 
remains controversial, with some studies showing strong immune response in the face of anti-HSV-
1 immunity (Brockmann et al., 2002), while another study showed a reduction in the immune 
response to a transgene, with the intensity of the reduction depending on the route of inoculation 
(Lauterbach et al., 2005).                                                                             .
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PURPOSE 
 
 
Rotaviruses are the most common cause of severe gastroenteritis among young children worldwide. 
These viruses are responsible for more than 600 000 deaths each year (Parashar et al., 2003). While 
the incidence of Rotavirus disease is similar for developed and developing countries, death from 
Rotavirus disease is most frequent in developing countries of sub-Saharan Africa and Asia, where 
patients may not always receive adequate medical attention quickly enough. The burden of 
Rotavirus infections highlights the urgent need for the development of an effective prophylactic 
anti-Rotavirus vaccine that would have universal application as part of childhood immunization 
programs. 
In 2006 two Rotavirus vaccines was licensed: Rotarix
®
 and Rotateq
®
. Rotarix
® 
is manufactured by 
GlaxoSmithKline and it is based on a live-attenuated G1P[8] human Rotavirus; Rotateq
® 
is 
produced by Merck and it is a mixture of five human-bovine reassortant Rotaviruses that expressed 
either human G1, G2, G3 or G4 VP7s, and a human P[8] VP4 on the bovine WC3 backbone 
(Vesikari, 2008).  
These vaccines have performed better in developed than in non-developed countries, probably due 
to inhibition by higher natural exposition before vaccination, or atypical serotypes prevalence in 
less developed countries (Bresee et al., 1999). In addition, adverse events correlated with the use of 
human vaccines based on infectious animal Rotaviruses have already been described; in fact, a 
previous human-simian reassortant Rotavirus vaccine, Rotashield
®
, was withdrawn from the market 
because of an association with intestinal intussusception (Murphy et al., 2001). Finally, Rotaviruses 
are constantly and rapidly evolving, due both to their segmented genomes and to the fact that genes 
can reassort between strains coinfecting a same host (Maunula et al., 2002; Steyer et al., 2008). This 
fact is an important threat to the rational of using live attenuated Rotavirus strains as vaccines, both 
because these strains can revert to more virulent phenotypes and because these vaccine strains are 
being released to the nature in the faeces of the inoculated person, raising a considerable ecological 
concern. 
It is therefore critical to develop alternatives to this classical approach, both to generate a deeper 
understanding and to explore the potential of novel vaccination strategies. 
This experimental work is part of the HEVAR project. HEVAR (Herpesvirus-based vaccines 
against Rotavirus infections) is a collaborative project involving four academic laboratories from 
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four European countries (France, Switzerland, Germany, Italy) and four academic laboratories 
belonging to three South American countries (Argentine, Brazil, Uruguay). 
The goal of HEVAR project was the development of innovative genetic vaccines to fight Rotavirus 
infection, based on the use of replication-defective HSV-1 vectors. A lot of advantages are related 
with the use of HSV-1 defective recombinant vectors; these include a broad host cell range, the 
ability to efficiently infect a lot of mammalian species, including humans, mice, rabbits and pigs, 
and the very large transgene capacity of these vectors, which allow the simultaneous delivery of 
multiple transgenes expression (as required for virus-like particles construction). 
The aim of this work was to produce HSV-1 based vectors expressing Rotavirus antigens. 
As first step Rotavirus genes encoding for structural proteins VP2, VP4, VP6 and VP7 were cloned  
from mouse Rotavirus strain (EC), human strains (Wa and Ds), and from simian strain (RRV) in 
basic plasmids such as pcDNA Hygro 3.1(+) or 3.1(-) or in pBSSK. In a second step, they were 
cloned in plasmids that have HSV-1 sequences (pB41, pB5 or pgJHE plasmids), where the 
Rotavirus cassettes were inserted between these Herpes sequences in order to recombine them into 
the viral genomes. Homologous recombinations were carried out using replication-incompetent 
HSV-1 viruses that lack one or more genes encoding essential proteins: they are two triple mutants 
viral DNAs (T0ZGFP and THZ, deleted on three immediate early genes, that encoding for ICP4, 
ICP27, and ICP22 proteins) and the single mutant S0ZgJGFP viral DNA (deleted on the gene which 
encodes for ICP4 protein). ICP4 and ICP27 proteins are essential for replication of the virus. 
Finally the expression of the Rotavirus transgenes was evaluated by immunofluorescence and 
western blot techniques with specific antibodies. 
Future studies will cross the recombinant HSV-1 vectors carrying a single Rotavirus transgene in 
order to generate empty Rotavirus-like particles (VLPs). VLPs mimic the overall structure of virus 
particles without any requirement that they contain infectious genetic material (Roy et al., 2008), 
making them a promising safe alternative to the live virus vaccines for Rotavirus. 
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MATERIALS AND METHODS 
 
 
Plasmids 
pcDNA

3.1/Hygro(+) and pcDNA

3.1/Hygro(-) shuttle plasmids are manufactured by Invitrogen. 
pBSSK is produced by Stratagen.  
The pB41 plasmid, based on pBlueScript plasmid (pB) backbone, has NotI-HindIII UL41 HSV 
fragment (HSV genomic positions 90.145-91.631 and 92.230-93.858) with a 300 pb deletion 
(SmaI) in the transcription region of VHS where has been inserted an expression cassette with the 
HSV ICP0 immediate-early promoter, the lacZ gene and the endogenous UL41 polyA.  
The pB5 plasmid has the immediate-early ICP22 sequence (HSV genomic positions 131.398-
133.372 and 133.365-134.787) with the expression cassette containing HCMV immediate-early 
promoter and SV40/BGH polyA.  
pgJHE plasmid has the pTZ18U backbone where the expression cassette containing HCMV 
immediate-early promoter, the gfp gene and BGH polyA has been cloned between the sequences of 
Us5 locus, which encodes for a non-essential glycoprotein gJ (genomic position: 136308-138345). 
Plasmids containing vp2, 4, 6 and 7 genes from Rotavirus strains G1P8 Wa and G2P4 DS-1 were 
cloned and given us from the laboratory of prof. José Paulo Gagliardi Leite (Brazil); plasmids 
containing vp2, 4, 6 and 7 genes from murine Rotavirus EDIM-Cambridge strain (EC) and from the 
Rhesus monkey Rotavirus strain (RRV) were cloned and given us from the laboratory of prof. 
Mabel Berois (Uruguay). 
 
 
Plasmids constructions 
The Rotavirus genes were amplified from Gateway-PCR product or plasmid pJET1.2/blunt with 
PCR to introduce restriction site using specific primers from each gene in order to subclone the 
genes in basic plasmids such as pcDNA Hygro 3.1(+) or 3.1(-) or in pBSSK. PCR reactions were 
performed using the enzyme Platinum Taq DNA Polymerase High Fidelity (Invitrogen # 11304-
011), following the provider’s recommendations. In order to get the best results, the cycling 
conditions and the reaction were adjusted for each gene. The obtained cassettes with the Rotavirus 
genes under the transcriptional control of the human cytomegalovirus promoter from pcDNA Hygro 
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3.1(+) or 3.1(-) or the transcriptional control of the immediate early ICP0 HSV-1 promoter from 
pBSSK based-plasmid were, in a second step, cloned in plasmids that have HSV sequences. The 
Rotavirus cassettes were inserted between these Herpes sequences in order to recombine them into 
the viral genomes. All the enzymatic digestions were performed using New England BioLabs 
(NEB) restriction endonucleases, and under the conditions suggested by the manufacturer. After 
digestion, DNA was loaded on agarose gel, extracted by elettroelution and treated with 
phenol/chloroform purification. Fragments obtained were quantified on agarose gel or by 
spectrophotometer analysis. Ligations were performed using T4 DNA ligase (New England 
BioLabs). 
All the plasmid constructions are shown in Table 1. 
 
Original 
plasmids 
with RV 
genes 
Backbones plasmids 
pBSSK pcDNA 
Hygro 
3.1(+) or 
3.1 (-) 
pB41 
(HSV UL41 or 
VHS sequences) 
pB5 
(HSV Us1 or 
ICP22 
sequences)  
pgJ1HE 
(HSV US5 or 
gJ sequences) 
pGEM 
VP6 RRV 
 
EcoRI  EcoRI in EcoRI 
in p41ICP0lacZ 
and 
p41HCMVlacZ 
  
pGEM 
VP7 RRV 
 
XbaI - EcoRI  EcoRI - XbaI in 
p41ICP0lacZ 
(ICP0pr) 
  
pGEM 
VP6 EC 
 
NruI – EcoRV 
in EcoRV 
NruI – 
EcoRV in 
EcoRV 
NruI-XbaI in 
SmaI-XbaI 
p41ICP0lacZ and  
p41HCMVlacZ 
XbaI  
 
 
pHSV-
VP2 EC-
IRES-
EGFP 
HindIII-PmeI 
into HindIII-
EcoV 
NotI-PmeI 
into NotI-
EcoV of 
pcDNA3.1
(-) 
Nru-XbaI under 
HCMVpr. into 
SmaI-XbaI in 
p41ICP0lacZ 
 PmeI into 
PmeI  
pJet2.1 
VP4 EC 
 BglII-
XbaI into 
BamHI-
XbaI 
Nru-XbaI under 
HCMVpr. into 
SmaI-XbaI in 
p41ICP0lacZ  
  
pCR2.1 
TOPO 
VP4 WA 
 HindIII-
EcoV into 
HindIII-
EcoV 
  NheI-XhoI 
into  
NheI-XhoI 
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pCR 
blunt2 
TOPO 
VP4 DS 
 HindIII-
EcoV into 
HindIII-
EcoV 
Nru-XbaI into 
SmaI-XbaI under 
HCMVpr. into 
SmaI-XbaI in 
p41ICP0lacZ 
  
pCR4 
blunt 
TOPO 
VP7 WA 
 EcoRI into 
EcoRI 
EcoRI into EcoRI 
under ICP0 
promoter into 
p41ICP0lacZ 
  
pCR4 
TOPO 
VP7 DS 
 Pme-Not 
into EcoV-
Not 
  NheI-XhoI 
into  
NheI-XhoI 
 
 
 
 
Bacterial transformation and plasmid purification 
The plasmids obtained after ligation were used to transform chemically competent E.coli cells 
(DH5α, Invitrogen), using the chemical transformation procedure suggested by the manufacturer. 
Each transformation was spread on separate lysogeny broth (LB) agar plates, and the plates were 
incubated at 37°C overnight.  
A single colony from these plates was picked and inoculated as starter colture in 5 ml LB medium 
containing the appropriate selective antibiotic. After an overnight incubation at 37°C, mini 
preparative of plasmid was done (QIAGEN Plasmid Mini Kit). Otherwise, the 5 ml of liquid colture 
were diluted 1/100 into selective LB medium to perform a maxi preparative of plasmid (QIAGEN 
Plasmid Maxi Kit).  
 
 
Cell lines and culture conditions 
Vero (ATCC, Rockville, MD), Vero-derived 7b cells (expressing the HSV-1 immediate early gene 
products ICP4 and ICP27 required for virus replication), E5 (expressing ICP4) and MDBK cells 
were maintained in high glucose Dulbecco’s modified Eagle’s medium (Euroclone) supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 10% fetal bovine serum 
Table 1. Schematic representation of cloning strategies used for the production of plasmid carrying 
Rotavirus genes. 
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(Euroclone). The 7b cells were subjected monthly to 1 week long selection with 1 mg/ml G418 
(Roche).  
Cells were grown at 37°C in 5% CO2. 
 
 
Construction of recombinant HSV-1 vectors by homologous recombination in 
eukaryotic cells. 
Alterations of the HSV-1 genome in eukaryotic cells can be achieved in a number of ways. These 
usually require a process in which portions of the virus genome, which have been cloned into 
plasmid vectors, are first modified in vitro; then the modified sequences are introduced into the 
virus genome and recombinant viruses are selected. Several methods have been described to insert 
DNA sequences into the viral DNA. It is possible, however, to significantly enhance the frequency 
of recombination using a two-step method through homologous recombination in cultured cells 
(Krisky et al., 1997).  
 
 
HCMV
lacZ
UL 41 
right flank
UL 41 
left flank
UL 41 
left flank
UL 41 
right flank
PacI PacI
UL 41 
right flank
HCMV
lacZ
UL 41 
left flank
PacI PacI
UL 41 
right flank
UL 41 
left flank
UL 41 
right flank
transgene UL 41 
left flank
UL 41 
right flank
transgene UL 41 
left flank
UL
UL
UL
UL
US
US
US
USa      b
a      b
a      b
a      b
b’ a’
b’ a’
b’ a’
b’ a’
a   c
a   c
a   c
a’ c’
a’ c’
a’ c’
a’ c’
a   cUL 41 (vhs)
ΔUL 41:lacZ
ΔUL 41:transgene
Co-transfection and selection
for virus encoding the marker 
gene (marker transfer)
PacI digestion
Co-transfection and selection
for recombinant virus carrying
the transgene (marker rescue)
 
 
 
 
Figure 1. Schematic representation of PacI/PmeI system to modify HSV-1 genome. In this case, PacI 
strategies is used to insert reporter lacZ gene in the first step, and then to substituted it with a transgene. 
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The first step is the insertion of a reporter gene cassette flanked by PacI or PmeI restriction enzymes 
sites, not otherwise found in the viral genome. Green fluorescent protein (GFP) and lacZ are two 
convenient marker genes that allow easy selection of the mutated virus genome. The second step is 
the substitution of the reporter gene with a second foreign DNA, carrying the transgene of interest, 
by digestion of the vector DNA with PacI or PmeI to remove the reporter gene and subsequent 
repair of the vector genome by homologous recombination with a transgene expression plasmid 
(figure 1). Potential recombinants, identified by a “clear plaque” phenotype (not expressing GFP or 
β-galactosidase, as in the right panel of figure 2), arose at high frequency (80-100%). 
 
 
Figure 2: Plaque phenotype of a recombinant HSV-1 expressing both β-galactosidase (left panel) and GFP 
(middle panel) reporter genes. Compare with the “clear plaque” phenotype (right panel). 
 
Viral vectors carrying Rotavirus genes were created by recombining the linearized plasmids 
containing the Rotavirus expression cassette into different defective mutant HSV backbones 
previously digested with PacI or PmeI described in the result chapter using the previously 
described recombination method. 
To create recombinant vectors, 500 µl of HBS (HEPES 200mM; NaCl 135mM, KCl 5mM; 
destrosio 5mM e Na2HPO4 0.7mM at pH 7.05) were added with 5 µg of viral DNA cotransfected 
with 1 µg of linearized plasmid DNA and 30 µl 2M CaCl2 based on calcium phosphate 
transfection (CaPO4 method). The calcium-phosphate-DNA suspension was transfer drop by drop 
into 60 mm culture plates with a 80% confluent cell monolayer (7b for triple mutant viruses – 
T0ZGFP and THZ, or E5 for single mutant virus - S0ZgJGFP). 
Finally cells were incubate at 37° in 5% CO2 incubator until the appearance of viral foci (3-4 
days). 
Recombinant virus carrying Rotavirus genes were identified by a “clear plaque” phenotype for 
GFP under the fluorescent microscope or after X-gal staining. 
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Viral DNA extraction and Southern blot analysis 
Infected cells were collected and centrifuged for 15 minutes at 12000 rpm. The supernatant was 
removed and the pellet, consisting of cells containing the virus was resuspended in 200 μl of lysis 
buffer (10 mM Tris-HCl pH8, 10mM EDTA) containing 0.25 mg/ml proteinase K (stock 20 mg/ml 
Euroclone EMR02201) and placed in agitation at 37°C for the night. The next day DNA was 
extracted with phenol/chloroform/isoamyl alcohol (25:24:1; Ambion, Applied Biosystems) and 
chloroform-isoamyl alcohol (24:1; Ambion, Applied Biosystems), centrifuging each time for 3 
minutes at 10000 rpm. A double volume of cold absolute ethanol was added to the aqueous phase 
containing DNA, and precipitated at -80°C for 30 minutes. The DNA was then centrifuged at 
12000 rpm for 15 minutes, removing the supernatant. The pellet obtained was washed with 200 μl 
of cold 70% ethanol and centrifuged at 12000 rpm for 3 minutes, air dried and finally resuspended 
in sterile water. The resultant viral DNA mutants were digested with restriction enzymes, 
transferred in a Hybond-N+ nylon membrane and verified by Southern blot using the protocol 
described in RPN 3005 kit (Amersham Life Science, Italia). The Southern was revealed using ECL 
detection kit (RPN 3040, Amersham Life Science Italia). 
  
 
Extraction and purification of recombinant viruses. 
Once isolated the recombinant virus containing the desired insert, it is useful to produce a viral 
stock, in order to have large quantities of recombinant virus with a high concentrantion of plaque 
forming units (PFU). 
HSV-1 stocks were prepared by infecting the complementing 7b or E5 cells at a multiplicity of 
infection (MOI) of 0.05. Infected cells were harvested when a 100% cytopathic effect was reached. 
Recombinant viruses were extracted from infected cells by repeated sequences of freezing and 
thawing, concentrated by ultracentrifugation and then purified in an Optiprep gradient. Infected 
cultures were collected by scraping and the cellular pellet was separated from the supernatant by 
low speed centrifugation. Then, while the virus from infected cells was released by sequential 
freezing and thawing (3 cycles), the virus from the supernatant was concentrated by 
ultracentrifugation (JA-20 rotor, 20,000 rpm, 30 min., 4ºC). Thereafter, the virus collected from 
both pellet and concentrated supernatant was concentrated again by ultracentrifugation (rotor SW 
40Ti, 20,000 rpm, 30 min., 4ºC) and then purified in a self-generated Optiprep (Axis-Shield, 
Norway) gradient (NVT 65 rotor, 2.5 hours, 350,000 rcf). The band containing the purified virus 
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was collected by puncturing the tube side, concentrated again by ultracentrifugation, resuspended 
in steril cold PBS, and stored at –80°C. All stocks were titrated on complementing cells (7b or E5); 
final titers averaged from 1 x 10
8
 to 1 x 10
9 
PFU/ml. 
 
 
Western blotting 
Vero cells were infected with the recombinant vectors at 2.0 MOI. Following a 1 hour adsorption 
period, the infected cells were plated in six-well plates and incubated for 18 hours, 24 hours or 40 
hours at 37°C in 5% CO2. The samples were collected and submitted to electrophoresis on 12% 
sodium dodecyl sulfate-polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride 
membranes (Bio-Rad) and incubated with a rabbit polyclonal antibody anti-RV (which recognizes 
VP7, VP6, VP5 and VP2 Rotavirus proteins) diluted 1:1000, followed by a donkey anti-rabbit IgG 
peroxidase-linked secondary antibody (1:2500, GE Healthcare). Alternatively, another primary 
antibody was used, a guinea pig polyclonal antibody anti-RV (diluted 1:1000), which recognizes 
VP6 and VP2 Rotavirus proteins; the secondary antibody was rabbit anti-guinea pig IgG 
peroxidase-linked (1:2500, Open Biosystem). Immunocomplexes were detected by ECL detection 
kit (Amersham Biosciences). 
 
 
Immunofluorescence 
Infected cells were washed with PBS and fixed with 3.7% formaldehyde (in PBS) at room 
temperature for 15 minutes. Fixation was stopped with 0.1M glycine (in PBS) at room temperature 
for minimum 5 minutes. Then cells were permealized with 0.2% Triton (in PBS) at room 
temperature for 15 minutes. Cells were washed immediately with PBS and they were blocked in 
PBS added with 0.2% Triton and 3% BSA (PBS-T-BSA) at room temperature for minimum 15 
minutes. Then cells were incubated with rabbit polyclonal antibody anti-bovine Rotavirus (strain 
RF, produced by Didier Poncet and Anne Charpilienne, 1:100) diluted in PBS-T-BSA at room 
temperature for 1 hour. Then the non-linked antibody was washed away with PBS, and cells were 
incubated with secondary antibody (goat anti rabbit IgG conjugated with Alexa Fluor 568, 1:2000, 
Invitrogen). After another wash in PBS, cells were incubated with DAPI (1 µg/ml) at room 
temperature for 15 minutes. Finally cells were washed with PBS and observed under fluorescence 
microscope (Nikon Eclipse E600, 100X oil immersion objective). 
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HSV-1 based vectors used in this project 
Viral vectors carrying Rotavirus genes were created by recombining the linearized plasmids 
containing the Rotavirus expression cassettes into different defective mutant HSV backbones.  
The results have been obtained based on HSV-1 backbone recombinant vectors devoiced of 
immediate early genes and incapable to produce an infectious progeny. Replication-defective HSV-
1 viruses show the capacity of infectivity and immunogenicity of a wild-type HSV, but are much 
safer due to the incapacity to replicate and to express viral proteins after infection.  
 
More in detail the three recombinant backbones used in this thesis were: 1) T0ZGFP which is a 
replication-defective HSV-1 viral vector that has low toxicity due to the deletion of three immediate 
early genes (ICP4, ICP27, essential for viral replication and ICP22) and contains the gfp gene and 
the lacZ gene as marker genes respectively into the ICP22 locus and the UL41 locus, which encodes 
for the virion-associated host shutoff protein (VHS, that is a tegument protein involved in the 
destabilization/degradation of infected cell mRNAs and prevents the DC maturation); 2) THZ 
(named also 4-27-22-), which is a replication-defective HSV-1 viral vector deleted on three 
immediate early genes (ICP4, ICP27, which are essential for viral replication and ICP22) and 
contains the lacZ gene into the ICP22 locus; 3) the last vector used in the project was S0ZgJGFP 
which is deleted in one out of five immediate early genes (ICP4-) and in the UL41 locus by the 
insertion of lacZ reporter gene flanked by PacI restriction sites and the GFP cDNA expression 
cassette, flanked by PmeI restriction sites, interrupting the Us5 locus that has been described to be 
involved in the inhibition of apoptosis in infected cells by antagonizing Fas ligand and grB- 
mediated pathways of CTL-induced apoptosis leading to an incomplete control of the infections by 
the immune system response. 
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Plasmids construction 
To develop different types of defective HSV-1-based vectors against Rotavirus infections, some RV 
structural proteins were chosen from mouse (EC), human (Wa and DS) and simian (RRV) 
Rotavirus strains as possible antigens capable to induce immunity and protect mice against a lethal 
Rotavirus challenge; they are VP2, VP4, VP6 and VP7 structural proteins. 
The Rotavirus genes as shown in table 1, amplified by PCR from Gateway system plasmid, were 
subcloned in basic plasmids such as pcDNA Hygro 3.1(+) or 3.1(-) or in pBSSK under HCMV 
promoter or ICP0 promoter and in a second step, in plasmids that have HSV sequences describe 
below; the Rotavirus cassettes were inserted between these Herpes sequences in order to recombine 
them into the viral genomes.  
The pB41 plasmid, based on pBlueScript plasmid (pB) backbone, has NotI-HindIII UL41 HSV 
fragment (HSV genomic positions 90.145-91.631 and 92.230-93.858) with a 300 pb deletion 
(SmaI) in the transcription region of VHS where has been inserted an expression cassette with the 
HSV ICP0 immediate-early promoter the lacZ gene and the endogenous UL41 polyA. The pB5 
plasmid has the immediate-early ICP22 sequence (HSV genomic positions 131.398-133.372 and 
133.365-134.787) with the expression cassette containing HCMV immediate-early promoter and 
SV40/BGH polyA. pgJHE plasmid has the pTZ18U backbone where the expression cassette 
containing HCMV immediate-early promoter, the egfp gene and BGH polyA, has been cloned 
between the sequences of Us5 locus, which encodes for a non-essential glycoprotein gJ (genomic 
position: 136308-138345). 
 
 
 
RV 
GENES 
FINAL PLASMIDS 
pB41 
(HSV UL41 or VHS 
sequences) 
pB5 
(HSV Us1 or ICP22 
sequences) 
pgJ1HE 
(HSV US5 or gJ1     
sequences) 
 
 
VP2 
EC 
p41HVP2EC
10 4 4 4  bp
V P2 E C
1486 41flank
1624 41 flank
UL38
UL41
CMV forward primer
T7 primer
T7 promoter
SmaI (776 2)
PmeI (710 6 )
NotI (20 24 )
NotI (774 7)
NotI (10 4 33) Hind III (336 )
Hind III (4 9 33)
Hind III (7113)
 
 
pgJHVP2EC
9 0 39  bp
US5
US4
Amp
V P2 E C
US3
CMV forward primer
T7 primer
CMV promoter
T7 promoter
f1 ori
US6
US5
US4
US4
Hind III (6 17)
Hind III (5714 )
PmeI (4 9 9 4 )
PmeI (570 7)
NotI (6 34 8 )
NotI (9 0 34 )
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VP4 
EC 
p41HVP4EC
9 4 6 1 bp
1624 41 flank
1486 41flank
VP 4EC
UL41
UL38
CMV forward primer
T7 primer
CMV promoter
T7 promoter
XbaI (1)
 
  
 
 
VP4  
Wa 
  
pgJHVP4Wa
8 16 2 bp
US5
US4
Amp
WA V P4
US3
HCMV
TOP O binding site
TOP O binding site
f1 ori
US6
US5
US4
US4
EcoR V (5727)
NheI (1)
X hoI (570 2)
Hind III (1308 )
Hind III (8 14 7)
 
 
 
VP4 
DS 
 
 
p41HVP4DS
9 514  bp
1624 41 flank
1486 41flankDS  V P4
UL41
UL38
CMV forward primer
T7 primer
CMV promoter
T7 promoter
TOP O binding s ite
TOP O binding s ite
XbaI (1)
EcoR V (36 3)EcoR V (9 4 8 8 )
Hind III (14 71)
Hind III (6 0 6 8 )
Hind III (70 6 5)
 
  
 
 
 
 
 
 
VP6 
EC 
 
 
 
 
p410VP6EC
78 9 8  bp
1486 41flank
1624 41 flank
ICP 0 promoter
UL38
UL41
EcoR V (156 9 )
X baI (1)
X baI (120 7)
SmaI (756 8 )
SmaI (7715)
SmaI (78 57)
EcoR I (14 5)
EcoR I (79 6 )
EcoR I (78 4 3)
 
pB5HVP6EC
8 528  bp
amp
Intron 2
ICP22 flank 1970 bp
BGH polyA
ICP22 flank 1320 bp
US 1
US 2
Rep Origin 2
Repeat Unit 10
NruI (5312)
NruI (6 6 39 )
EcoR I (4 6 23)
EcoR I (74 6 0 )
EcoR I (8 111)
XbaI (29 )
XbaI (4 4 76 )
XbaI (8 522)
 
 
p41HVP6EC
8 305 bp
1624 41 flank
1486 41flank
UL41
UL38
T7 primer
CMV forward primer
CMV promoter
T7 promoter
EcoR V (16 11)
XbaI (4 3)
XbaI (124 9 )
EcoR I (18 7)
EcoR I (8 38 )
 
 
 
 
VP6 
RRV 
p410VP6RRV
79 0 4  bp
1486 41flank
1624 41 flank
ICP 0 promoterV P6RRV
UL38
UL41
EcoR I (1)
EcoR I (6 6 9 3)
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VP6 
RRV 
 
 
p41HVP6RRV
8 373 bp
V P6RRV 1624 41 flank
1486 41flank
UL41
UL38
T7 primer
CMV forward primer
CMV promoter
T7 promoter
EcoR I (6 4 14 )
EcoR I (76 26 )
 
  
 
 
VP7 
EC 
p410VP7EC
759 4  bp
ICP 0 promoter
1624 41 flank
1486 41flank
UL41
UL38
NcoI (4 74 )
EcoR I (8 6 8 )
EcoR I (7554 )
Hind III (238 8 )
Hind III (6 9 8 5)
X baI (8 57)
X baI (9 18 )
PacI (1)
PacI (9 0 3)
 
  
 
 
VP7 
RRV 
p410VP7RRV
754 2 bp
1486 41flank
1624 41 flank
ICP0 promoter
UL38
UL41
EcoR I (1)
XbaI (6 6 37)
 
  
 
 
VP7 
Wa 
p410VP7Wa
7714  bp
VP 7 Wa
ICP0 promoter
1624 41 flank
1486 41flank
UL41
UL38TOP O binding site
TOP O binding site EcoR I (1)
EcoR I (6 6 9 3)
 
  
 
 
VP7 
DS 
 
 
pgJHVP7Ds
6 8 4 7 bp
US5
US4
Amp
DS VP 7
US3
HCMVTOP O binding site
TOP O binding site
f1 ori
US6
US5
US4
US4
NheI (1)
NotI (570 8 )
X hoI (570 2)
PmeI (56 8 5)
PmeI (6 8 4 3)
 
 
 
 
 
Construction of replication-defective HSV-1 vectors 
Plasmid carrying murine or rhesus VP6 and VP7 Rotavirus genes flanked by HSV viral sequences 
were integrated in the viral genome by homologous recombination using the Pac-facilitated lacZ 
substitution method (Krisky et al. 1997) described in Material and Methods chapter. Genetically 
Table 1. Plasmids obtained by cloning Rotavirus genes in pB41, pB5 or pgJ1HE plasmids.  
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recombinations have been carried out using standard calcium phosphate transfection of 5 µg of 
T0ZGFP or THZ (named also 4-27-22-) viral DNAs (previously described) and 1 µg of linear 
recombination plasmids pB41VPs or pB5VPs. Transfection and isolation of the recombinant 
viruses were performed in 7b (modified Vero cells) capable of providing the essential ICP4 and 
ICP27 HSV gene products. The recombinant viruses (T0VPsGFP, THVPsGFP or 4-27-22VPs) 
containing the Rotavirus cDNAs were identified by isolation of a clear plaque phenotype after X-
gal staining. The protein expression from the recombinants was evaluated by immunofluorescence 
and Western blot techniques with specific mono/polyclonal antibodies. 
All the recombinant viruses derived from T0ZGFP have green plaque phenotype under the 
fluorescent microscope because of the presence of gfp gene in US1 locus, but clear plaque 
phenotype after X-gal staining for the sostitution of lacZ gene with the Rotavirus cassettes. 
 
The recombinant viruses obtained by homologous recombination of Rotavirus genes into T0ZGFP 
genome are represented in figure 1. 
 
 
 
 
 
 
ICP0 LacZ 
HCMV GFP 
T0ZGFP UL41 
ICP4 ICP4 ICP22 
ICP27 
41 flank  ICP0 VP6 EC 
41 flank 
41 flank 
41 flank 
ICP0 
HCMV 
ICP0 
VP6 RRV 
VP6 RRV 
VP7 EC 
41 flank 
41 flank 
41 flank 
41 flank 
41 flank ICP0 VP7 RRV 41 flank 
Name of the recombinant virus 
T0VP6EC 
T0VP6RRV 
THVP6RRV 
T0VP7EC 
T0VP7RRV 
Figure 1. Schematic representation of recombinant viruses obtained by insertion of Rotavirus cassettes 
into UL41 locus of T0ZGFP. 
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The THVP6EC recombinant virus obtained by homologous recombination of Rotavirus gene into 
THZ genome is represented in figure 2. 
 
 
The last set of recombinant vectors were done based on S0ZgJGFP backbone, as previously 
described. In this backbone, due to the PacI and PmeI restriction sites, two loci were selected for 
transgene insertion. The replication-defective recombinant viruses expressing Rotavirus proteins 
were generated from the HSV-1 vectors S0ZgJGFP by homologous recombination as previously 
done. Transfection and isolation of the recombinant viruses were performed in E5 (modified Vero 
cells) capable of providing the essential ICP4 HSV gene product. The recombinant viruses 
(SHVPs/gJHE, SHZgJVPs, S0VPs/gJHE or S0ZgJVPs) containing the Rotavirus cDNAs were 
identified by isolation of a clear plaque phenotype for GFP under the fluorescent microscope or 
after X-gal staining.  
 
Some recombinant viruses were constructed after the insertion of Rotavirus gene in UL41 locus of 
S0ZgJHE (as describe in figure 3); these viruses have green plaque phenotype under the fluorescent 
microscope because of the presence of gfp gene in US5 locus, but clear plaque phenotype after X-
gal staining for the sostitution of lacZ gene with the Rotavirus cassettes. 
 
 
LacZ HCMV 
THZ 
ICP4 ICP4 ICP22 
ICP27 
 
ICP22 flank HCMV VP6 EC ICP22 flank 
Name of the recombinant 
virus 
4
-
27
-
22VP6EC 
Figure 2. Schematic representation of recombinant viruses obtained by insertion of Rotavirus cassette 
into US1 (or ICP22) locus of THZ. 
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Other recombinant viruses were constructed after the insertion of Rotavirus gene in US5 locus of 
S0ZgJHE (as describe in figure 4); these viruses have blue plaque phenotype after X-gal staining 
because of the presence of lacZ gene in UL41 locus, but clear plaque phenotype under the 
fluorescent microscope due to the sostitution of gfp gene with the Rotavirus cassettes. 
 
 
ICP0 LacZ 
HCMV GFP 
S0ZgJHE UL41 
  ICP4 ICP4 Us5 (gJ) 
41 flank  VP6 EC 
41 flank 
41 flank 
41 flank 
HCMV 
VP2 EC 
VP4 EC 
VP4 DS 
41 flank 
41 flank 
41 flank 
41 flank 
HCMV 
41 flank 41 flank 
HCMV 
HCMV 
ICP0 VP7 Wa S0VP7WagJHE 
SHVP4DSgJHE 
SHVP4ECgJHE 
SHVP2ECgJHE 
Name of the recombinant  
virus 
SHVP6ECgJHE 
Figure 3. Schematic representation of recombinant viruses obtained by insertion of Rotavirus cassettes 
into UL41 locus of S0ZgJHE. 
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All the recombinant viruses done in the project have been purified by three rounds of limiting 
dilution and the presence of the transgenes was verified by Southern blot analysis. The protein 
expression was evaluated by immunofluorescence and Western blot techniques with specific 
mono/polyclonal antibodies. 
 
 
Analysis of Rotavirus protein expression 
Expression of Rotavirus protein was assessed by Western blot analysis. Vero fibroblasts were 
infected with the different recombinant replication-defective HSV-1 vectors previously described 
and Rotavirus gene expression analysed by Western blot after 18, 24, and 40 hours post-infection 
(hpi). 
Each Western blot analysis have been standardized by the expression of the alfa-actin housekeeping 
gene as internal control to correct for any differences in loading of the gel with the protein of 
interest and to normalize the data (data not shown). 
ICP0 LacZ 
HCMV GFP 
S0ZgJHE UL41 
ICP4 ICP4 Us5 (gJ) 
 
VP7 DS HCMV 
Us5 flank 
HCMV VP4 Wa 
HCMV VP2 EC 
HCMV VP6 EC 
Us5 flank 
Us5 flank 
Us5 flank 
Us5 flank 
Us5 flank 
Us5 flank 
Us5 flank S0ZgJVP7DS 
S0ZgJVP4Wa 
S0ZgJVP6EC 
S0ZgJVP2EC 
Name of the recombinant 
virus 
Figure 4. Schematic representation of recombinant viruses obtained by insertion of Rotavirus cassettes 
into US5 locus of S0ZgJHE. 
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VP6 Rotavirus protein expression 
As first, the VP6 EC and VP6 RRV expression was studied. To perform this analysis, Vero cells 
were infected with T0VP6EC and T0VP6RRV recombinant viruses at 2 MOI (molteplicity of 
infection). Two different positive controls were used: one is a sample of Vero cells transfected with 
an amplicon expressing VP6 EC protein (C+1, given us by Cornel Fraefel’s group), and the other is 
purified Rotavirus strain SA 11 (C+2, given us by Graciela Glikman’s group from Argentina). As 
negative controls were loaded one sample of non infected Vero cells and one sample of Vero cells 
infected with T0ZGFP (the mutant backbone). All the samples were collected at 24 hpi. In figure 5 
the bands corresponding to the lines where Vero cells infected with T0VP6EC or T0VP6RRV were 
loaded are positive to the antibody against VP6. 
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Then the expression of vp6 EC gene cloned into UL41 locus of S0ZgJHE (or S0ZgJGFP) backbone 
was studied. To perform also this analysis Vero cells were infected with SHVP6ECgJHE 
recombinant virus. As positive control was used purified Rotavirus strain SA 11 (C+). As negative 
controls were used non-infected Vero cells and Vero cells infected with S0ZgJHE (the mutant 
backbone) or K0S virus (wild type Herpes virus). All the infections were done at 2 MOI. The 
experiment was performed (and the cells were collected) at 18 hpi (hours post infection) and 40 hpi.  
Figure 5. Western blot of T0VP6EC and T0VP6RRV viruses. 
RESULTS 
 60 
C
+
M
W
S
H
V
P
6
E
C
g
JH
E
S
0
Z
g
JH
E
K
O
S
V
E
R
O
C
+
M
W
S
H
V
P
6
E
C
g
JH
E
S
0
Z
g
JH
E
K
O
S
V
E
R
O
C
+
M
W
S
H
V
P
6
E
C
g
JH
E
S
0
Z
g
JH
E
K
O
S
V
E
R
O
C
+
M
W
S
H
V
P
6
E
C
g
JH
E
S
0
Z
g
JH
E
K
O
S
V
E
R
O
 
 
 
 
In this Western blot a line corresponding to VP6 protein was visible where total Vero cell lysates 
infected with SHVP6ECgJHE recombinant virus was loaded; the protein shows a stronger 
expression at 40 hpi than at 18 hpi. 
Finally, other two recombinant viruses carrying vp6 Rotavirus gene were constructed and purified; 
after the production of their viral stocks, a Western blot with Vero cells infected with five different 
types of recombinant viruses expressing VP6 Rotavirus protein (EC or RRV) was performed. They 
are T0VP6EC, T0VP6RRV and SHVP6ECgJHE (as previously described), and in addition Vero 
cells infected with THVP6RRV (carrying vp6 RRV gene into UL41 locus of T0ZGFP triple mutant, 
under HCMV promoter) and 4
-
27
-
22VP6 EC (with vp6 EC gene into US1 locus of 4-27-22- or THZ 
triple mutant, under HCMV promoter) were loaded. Purified Rotavirus strain SA 11 served as 
positive control (C+) and as negative controls non-infected Vero cells and Vero cells infected with 
S0ZgJHE (the single mutant backbone), or K0S virus (wild type Herpes virus). All the infections 
were done at 2 MOI, and cells were collected at 24 hpi. 
 
Figure 6. Western blot of SHVP6ECgJHE virus. 
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In the Western blot, shown in figure 7, a line corresponding to VP6 protein (41 kDa) was visible in 
all the samples of Vero cells infected with recombinant viruses carrying vp6 Rotavirus gene.  
The main problem in protein detection is the absence of commercial and well-tested antibodies 
against murine and simian Rotavirus proteins. For these experiments have been used different 
antibodies, obtained from coworkers involved in the project, against VP6 Rotavirus protein to try to 
overcome the problem of the high background and low specificity against the strains that have been 
used in this project. The antibodies used were: rabbit anti-Rotavirus serum from G.Glikman, 
Buenos Aires, rabbit anti-Rotavirus polyclonal serum or a guinea pig anti-Rotavirus polyclonal 
serum, these last two raised against an isolated Rotavirus (Environmental isolate Env25, G8P1, A. 
Metzler, University of Zurich, Switzerland).  
 
 
Evaluation of T0VP6RRV ability to express the VP6 product in non-permissive cells 
The ability of T0VP6RRV to express the VP6 protein was assayed also by infection of cultures of 
several mammalian cell lines followed by extraction and VP6 detection through Western-blot, using 
an anti-VP6 monoclonal antibody. Confluent cultures of the cell lines Vero (African green monkey 
kidney cells), Gli36 (human glioblastoma cells) and MDBK (Madin-Darby bovine kidney cells) 
were infected with either T0VP6RRV or T0ZGFP (control virus) at a multiplicity of 1 MOI in 6-
Figure 7. Western blot of all recombinant virus produced expressing VP6 Rotavirus protein. 
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wells culture plates. Infected cultures and negative controls were collected at 24 hours post 
infection and the presence of VP6 was detected with a specific monoclonal antibody (CEVAN, 
Argentina), followed by a peroxidase conjugated anti-mouse antibody. The result can be observed 
in Figure 8. 
 
 
 
Figure 8. Western-blot detection of VP6 RRV expression in cultures of different cell lines infected with 
T0VP6RRV. Lane 1: positive control of VP6 RRV expressed in baculovirus; lane 2: molecular size markers 
(Bio-Rad Cat. Nº: 161-0318); lane 3: infected Vero cells; lane 4: mock-infected Vero cells; lane5: infected 
Gli36 cells; lane 6: mock-infected Gli36 cells; lane 7: infected MDBK cells; lane 8: mock-infected MDBK 
cells; purified suspension of the RRV strain of Rotavirus 
 
 
The monoclonal antibody (CEVAN, Argentina) used in this experiment was very specific for this 
VP6 strain and has detected the viral protein with no background in Western blots. Unfortunately 
the antibody was not more available for other experiments.  
 
 
VP2 Rotavirus protein expression 
The expression of murine vp2 EC transgene into US5 locus of S0ZgJHE (or S0ZgJGFP) backbone 
was studied. To perform this analysis, Vero cells were infected with S0ZgJVP2EC recombinant 
virus. As positive control was used the purified Rotavirus strain SA 11. As negative controls were 
used Vero cells infected with K0S virus (wild type Herpes virus) and non-infected cells. All the 
infections were done at 2 MOI, and cells were collected at 24 hpi. 
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The rabbit anti-Rotavirus polyclonal serum detects the viral VP2 94 kDa Rotavirus protein 
corresponding to the line where Vero cells infected with S0ZgJVP2EC was loaded (figure 9).  
 
VP2 and VP6 are readily detectable with the antibodies obtained from Zurich, Switzerland, but VP7 
is not detected as the serum was raised against another G-type. 
 
 
VP7 Rotavirus protein expression 
The expression of vp7 transgene was detected using the Western blot analisys. In the figure 10 is 
shown the expression of VP7 RRV into UL41 locus of T0GFP backbone. To perform this analysis, 
as previously described for the other recombinants, Vero cells were infected with T0VP7RRV 
recombinant virus. Purified Rotavirus strain SA 11 served as positive control, mock non-infected 
cells and mock-infected cells, with K0S virus (wild type Herpes virus) or with T0ZGFP triple 
mutant backbone, as negative controls. All infections were done at 2 MOI, and cells were collected 
at 24 hpi. 
 
 
Figure 9. Western blot of S0ZgJVP2EC virus. 
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Figure 10 shows the VP7 Rotavirus protein band corresponding at 34 kDa in the line where Vero 
cells infected with T0VP7 RRV was loaded. 
 
 
Immunofluorescence 
The expression of VP6 Rotavirus protein was evaluated also by using immunofluorescence 
technique. This type of experiment was performed both in Vero and MDBK cells, but the best 
results were obtained in MDBK cells (figure 11 and 12). 
MDBK cells were infected at 2 MOI respectively with T0VP6EC or T0VP6RRV recombinant 
viruses; in both of them vp6 Rotavirus gene (EC or RRV) was in UL41 locus of T0ZGFP backbone 
under ICP0 promoter, and cells infected with these viruses had green phenotype, because of the 
presence of gfp gene in US1 locus of T0ZGFP. Cell infections were stopped at 24 hpi. These cells 
were then incubated with rabbit polyclonal antibody anti-bovine Rotavirus strain RF (produced by 
Didier Poncet, Anne Charpilienne); the secondary antibody was goat anti-rabbit IgG, conjugated 
with Alexa 568. 
Figure 10. Western blot of T0VP7RRV virus. 
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A1  B1  C1    D1 
 
 
 
 
    
 
Figure 12. Immunofluorescence of T0VP6RRV virus. A1: DAPI staining; B1: GFP expression; C1: VP6 EC 
expression; D1: merge. 
 
A2  B2  C2    D2 
 
 
 
Cell nuclei were visible after DAPI staining and cells infected with T0VP6EC (figure 11) or 
T0VP6RRV (figure 12) were green because of GFP expression. In red is possible to see the 
nanotubes formed by VP6 protein; in fact, as known in literature, VP6 alone can form spherical or 
tubular aggregates, depending on conditions such as pH, ionic strength and divalent cation 
concentration (Lepault et al., 2001). 
In summary, we demonstrated the vector-mediated expression of the structural Rotavirus genes vp2, 
vp6 and vp7 in transduced mammalian cells using the HSV-1 based vector system. The weak 
protein expressions that have been shown in Western blot analysis can be explain by the lack of 
strong specificity of the antibodies against Rotavirus proteins used in the project. The commercial 
antibodies are mainly against bovine or human strains but not against simian or murine strains. 
Figure 11. Immunofluorescence of T0VP6EC virus. A1: DAPI staining; B1: GFP expression; C1: VP6 EC 
expression; D1: merge. 
Figure 12. Immunofluorescence of T0VP6RRV virus. A2: DAPI staining; B2: GFP expression; C2: VP6 
EC expression; D2: merge. 
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Another explanation for the low expression of the proteins expressed by the vectors may be due to 
the interferences between the recombinants and the Rotavirus genes, as HSV-1 is delivering the 
genome to the nucleus, but Rotavirus is replicating in the cytoplasm and it can make changes in 
splicing events.  
 
 
Evaluation of immune responses against HSV-based Rotavirus vaccines 
The animal experiments were done in Thomas Brocker’s laboratory, Ludwig-Maximilians-
Universitaet Muenchen. The major goals of the immunologists involved in the global project were 
to study if the recombinant vectors constructed in the HEVAR project were able to elicit both 
humoral and cellular specific responses, following different routes of immunization, in order to 
characterize the nature of these responses, and to explore the capacity of these vectors to induce 
protection after Rotavirus challenge.   
In one of these studies, three constructs expressing mouse or monkey Rotavirus VP6 protein were 
compared, one based on a recombinant defective vector (T0VP6RRV) and the others on amplicon 
recombinant vectors (pHSV-VP6 EC-EGFP, pHSV-VP6 RRV-EGFP). 
The immunization experiments were done using different routes of immunization: subcutaneous, 
intramuscular, intraperitoneal. 
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       Figure 13. In vivo experiment schedule. 
 
 
In these series of experiments (data not shown), the response to the recombinant vaccines was noted 
with amplicon vector expressing VP6 protein from EC strain but not with replication defective 
recombinant vector expressing VP6 from RRV strain (T0VP6RRV), even when this was used at 
higher doses. No response was also detected with amplicon vector expressing VP6 from RRV 
strain. At the time of these experiments, replication defective vectors expressing VP6 EC were not 
evalueted because they were under construction. 
The intramuscular administration of HSV-1-based vectors was the most effective route in terms of 
antibody production. In a 2-dose schedule, it was as effective as subcutaneous and intraperitoneal 
routes. However, antigen-specific IgG levels were detected after a single dose only by 
intramuscular administrations and only against HSV but not against RV antigens. 
 
 
Testing of immunogenicity and protection induced by HSV-1-based vectors 
expressing Rotavirus proteins 
The challenge model was done in Graciela Glikman’s laboratory, University of Quilmes (Buenos 
Aires, Argentina), based on previously work (Coffin SE et al., 1997) and adapted for this project. 
To set up the conditions of the challenge model, mice were immunized intramuscularly with 1,5 x 
10
5
 FFU of ECca strain (culture adapted EC strain) and on day 21 post infection animals were 
challenged intragastrically with 10
4
 SD50 of ECwtUNQ. Stool samples were collected 8 days after 
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challenge, shedding levels of RV were measured and the area under the curve (AUC) of shedding 
was determined.  
Protection from Rotavirus (RV) challenge was evaluated by comparing Ag shedding in vaccinated 
vs mock vaccinated animals. Sensitive measurement based on both duration and amplitude of 
shedding, was performed by calculating the area under the curve (AUC) of RV Ag concentration in 
stools along 8 days post challenge. 
The experiment was done, based on these challenge setting, following the schedule shown in figure 
14. The mice were immunized with one dose or two doses of VP6 recombinant vector. Control 
groups were given PBS, control vectors or control vaccine (im EC culture adapted). Mice were 
challenged 3 weeks after the second dose with live Rotavirus (10
4
 SD50 of EC wild type strain). 
The results obtained in vivo, after immunization with one dose or two doses (figure 15) of 
recombinant HSV vectors, have not shown detectable serum IgG or fecal IgA but also have not 
shown significant differences in shedding between controls and RV expressing recombinant vectors 
immunized mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Schedule of immunization and challenge experiment with recombinant T0VP6RRV and T0GFP. 
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Figure 15. Antibody response and shedding curve after recombinant vectors immunization and RV 
challenge. No detectable serum IgG or fecal IgA.  
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Figure 16. Antibody response and shedding curve after recombinant vectors immunization and RV 
challenge. No significant differences in shedding between controls and RV expressing recombinant vectors 
immunized mice. 
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DISCUSSION 
 
 
Rotaviruses (RVs) are the most important cause of acute gastroenteritis in humans and animals. 
These viruses cause diarrheal disease primarily in the young, but infection and disease in older 
children and adults can occur, resulting in more than 600 000 deaths per year, mainly in developing 
countries. Rotavirus infections cannot be controlled by hygiene and sanitation measures, with also 
immense medical and societal costs; therefore there is an urgent need for the development of an 
effective prophylactic anti-Rotavirus vaccine that would have universal application as part of 
childhood immunization programs. 
Currently, the most frequent approach to Rotavirus vaccine design is based on live attenuated 
strains (Rotarix
®
, produced by GlaxoSmithKline, and RotaTeq
®
, Merck). However, several major 
drawbacks have affected the development and application of these live Rotavirus-based oral 
vaccines, including the withdrawal from market of one of these vaccines (Rotashield, Wieth-
Lederle) because of adverse effects (gut intussusception). Moreover Rotaviruses, which are a 
nonenveloped double-stranded RNA viruses, are constantly and rapidly evolving, due to their 
segmented genomes and to the fact that their genes can reassort between strains coinfecting a same 
host, and this fact is an important threat to the rational of using live attenuated Rotavirus strains as 
vaccines, both because these strains can revert to more virulent phenotypes and because these 
vaccine strains are being released to the nature in the faeces of the inoculated person, raising a 
considerable ecological concern. It is therefore critical to develop alternatives to this classical 
approach, both to generate a deeper understanding and to explore the potential of novel vaccination 
strategies. 
Currently, replication-defective viral vectors are considered the most promising vehicles to deliver 
antigens for prophylactic and therapeutic vaccination, as well as for fundamental research, because 
of good cellular infectious activity in vitro and in vivo and genetic stability. 
This experimental work is part of HEVAR project. HEVAR (Herpesvirus-based vaccines against 
Rotavirus infections) is a collaborative project involving four academic laboratories from four 
European countries (France, Switzerland, Germany, Italy) and four academic laboratories belonging 
to three South American countries (Argentine, Brazil, Uruguay). 
The goal of HEVAR project is the development of innovative genetic vaccines to fight against 
Rotavirus, based on the use of replication-defective HSV-1 vectors. 
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The use of HSV-1- based vectors offers an attractive strategy to develop Rotavirus vaccines. In fact, 
HSV can infect most cell types, quiescent or in proliferation, from a lot of mammalian species, 
including humans, mice, rabbits and pigs; moreover, HSV vectors have a very large transgene 
capacity, allowing the simultaneous delivery of multiple transgenes expression (as required for 
virus-like particles construction). HSV recombinants can be designed to be very safe vectors, 
through modifications that make them replication incompetent; in particular, the vectors used in this 
project were deleted of the gene encoding ICP4 alone or together with the gene encoding ICP27, 
two genes essential for viral replication. 
In the first part of this project the cloning, sequencing and validation of the structural Rotavirus 
genes from mouse, monkey, and two human Rotavirus strains into plasmids were done to construct 
a large number of HSV-1 recombinant vectors, expressing single or combined Rotavirus antigens. 
In this way it was possible to create a library of HSV-1-based recombinant vectors expressing 
Rotavirus genes; vectors carrying a single exogenous gene represent a useful tool to research about 
the specific features of each gene. The expression profiles of these vectors and the localization of 
the expressed protein have been characterized in infected cells, both by Western blotting and 
immune-fluorescence studies.  
The recombinant vectors expressing the Rotavirus proteins are in use now to perform the 
immunologic studies. The final goal of this project was to evaluate the ability of HSV vectors to 
elicit protective immune responses against Rotavirus infection in normal and transgenic mice, 
therefore helping to elucidate the contribution of individual Rotavirus antigens, and of different 
components of the immune system, to the architecture of the immune response and to protection 
upon Rotavirus challenge in this animal model. In the first serie of experiments, the responses to 
VP6 Rotavirus specific peptides was noted mainly with amplicons vectors expressing VP6 protein 
from EC strain (these vectors are made by the partner from Zurich) but no with recombinant 
vectors, even when these were used at higher doses. The challenge experiments have evidentiated 
no protection from immunized animal against Rotavirus infection.  
The hypothesis of the negative results obtained in vitro (feeble bands in Western blot analysis) and 
in vivo experiments (lack of effective response against RV antigens and failure in protection from 
RV infection) can be attributed to the low expression of the proteins expressed by the vectors which 
is may be due to the interferences between the recombinants and the Rotavirus genes; it will be 
interesting to investigate the RNA of the infected cells for possible splicing events, as HSV-1 is 
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delivering the genome to the nucleus, but Rotavirus is replicating in the cytoplasm. In the future to 
overcome unwanted splicing events we will plan to block them by using drugs that will inhibit 
spliceosomes to demonstrate if can be increased the full length of VP6. The results that can be 
obtained from this basic study can help in future to generate empty Rotavirus-like particles (VLPs) 
from recombinant HSV-1 vectors carrying different Rotavirus transgene. VLPs mimic the overall 
structure of RV virus (Roy et al., 2008), making them a promising safe alternative to the live virus 
vaccines for Rotavirus.                                                                   .
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